1 | � | 2,038 |
2 | �¹ | 1,165 |
3 | kg� | 303 |
4 | 10� | 215 |
5 | �� | 178 |
6 | fev� | 172 |
7 | ₂ | 163 |
8 | m� | 158 |
9 | ca²� | 150 |
10 | ori | 142 |
11 | ml� | 133 |
12 | cd4� | 129 |
13 | ₀ | 116 |
14 | l� | 110 |
15 | min� | 105 |
16 | h� | 101 |
17 | ¹� | 83 |
18 | t� | 82 |
19 | �² | 68 |
20 | g� | 64 |
21 | k� | 51 |
22 | d� | 50 |
23 | �/l | 47 |
24 | b� | 45 |
25 | cd8� | 41 |
26 | day� | 41 |
27 | signi� | 40 |
28 | �/� | 40 |
29 | na� | 39 |
30 | //www.trialregister.nl/trialreg/admin/rctview.asp | 38 |
31 | ¹³� | 38 |
32 | �cs | 38 |
33 | a� | 37 |
34 | f� | 36 |
35 | s� | 35 |
36 | hba� | 34 |
37 | �c | 34 |
38 | �³ | 34 |
39 | �¹·min� | 34 |
40 | mg²� | 32 |
41 | mg� | 32 |
42 | cant | 30 |
43 | nad� | 29 |
44 | log� | 28 |
45 | yb³� | 28 |
46 | δ� | 28 |
47 | coq� | 27 |
48 | 10-3 | 26 |
49 | β� | 26 |
50 | ₇ | 26 |
51 | +/ | 25 |
52 | ₆ | 24 |
53 | c� | 23 |
54 | ml·kg� | 23 |
55 | at� | 22 |
56 | cantly | 22 |
57 | non-m� | 22 |
58 | ²� | 22 |
59 | q� | 19 |
60 | hco₃� | 18 |
61 | ₅ | 18 |
62 | �n | 18 |
63 | cb� | 17 |
64 | cd3� | 17 |
65 | cu²� | 17 |
66 | fb� | 17 |
67 | α� | 17 |
68 | �s | 17 |
69 | cd14� | 16 |
70 | e� | 16 |
71 | hiv� | 16 |
72 | mg·kg� | 16 |
73 | n� | 16 |
74 | sasa | 16 |
75 | �-thc | 16 |
76 | �ga | 16 |
77 | er³� | 15 |
78 | no₂� | 15 |
79 | //www.anzctr.org.au/trial_view.aspx | 14 |
80 | ham-d� | 14 |
81 | p2� | 14 |
82 | sca� | 14 |
83 | ₉₇ | 14 |
84 | //www.anzctr.org.au/trial/registration/trialreview.aspx | 13 |
85 | nd³� | 13 |
86 | p2y� | 13 |
87 | src� | 13 |
88 | vldl� | 13 |
89 | ¹²� | 13 |
90 | �-atpase | 13 |
91 | adh� | 12 |
92 | fe²� | 12 |
93 | fe³� | 12 |
94 | l·min� | 12 |
95 | r� | 12 |
96 | x̃ | 12 |
97 | zn²� | 12 |
98 | δ¹� | 12 |
99 | a1� | 11 |
100 | al³� | 11 |
101 | no₃� | 11 |
102 | o� | 11 |
103 | post� | 11 |
104 | ×10� | 11 |
105 | �f | 11 |
106 | afb� | 10 |
107 | auc₀₋� | 10 |
108 | chos� | 10 |
109 | hg²� | 10 |
110 | ho³� | 10 |
111 | ³� | 10 |
112 | �-tetrahydrocannabinol | 10 |
113 | �i | 10 |
114 | �¹·d� | 10 |
115 | ag� | 9 |
116 | cm� | 9 |
117 | con� | 9 |
118 | eu³� | 9 |
119 | medizinischen | 9 |
120 | mg.kg� | 9 |
121 | mol� | 9 |
122 | pm� | 9 |
123 | p� | 9 |
124 | rnica | 9 |
125 | t1� | 9 |
126 | week� | 9 |
127 | ¹³c� | 9 |
128 | ₋₃� | 9 |
129 | acth� | 8 |
130 | au³� | 8 |
131 | ce³� | 8 |
132 | cmh2o� | 8 |
133 | et-1� | 8 |
134 | identi� | 8 |
135 | la� | 8 |
136 | ser� | 8 |
137 | tgf-β� | 8 |
138 | vanc� | 8 |
139 | v� | 8 |
140 | ódź | 8 |
141 | ₀₄₋₃₆₃ | 8 |
142 | �l� | 8 |
143 | �¹·1.73 | 8 |
144 | /₂ | 7 |
145 | a-stimulated | 7 |
146 | alpha� | 7 |
147 | co²� | 7 |
148 | igt� | 7 |
149 | min₋� | 7 |
150 | mmol·l� | 7 |
151 | oxycodone� | 7 |
152 | o₂� | 7 |
153 | pdapp� | 7 |
154 | pga� | 7 |
155 | vi-crm� | 7 |
156 | w� | 7 |
157 | ₉ | 7 |
158 | �cr | 7 |
159 | �f-nifrolene | 7 |
160 | �¹·h� | 7 |
161 | 5-ht� | 6 |
162 | beats·min� | 6 |
163 | ch2� | 6 |
164 | dl� | 6 |
165 | gpat1� | 6 |
166 | h₅/h� | 6 |
167 | mg·g� | 6 |
168 | mg·l� | 6 |
169 | mg∙kg� | 6 |
170 | mmhg₋� | 6 |
171 | mn²� | 6 |
172 | nk� | 6 |
173 | pmol·kg� | 6 |
174 | sorry | 6 |
175 | vegf� | 6 |
176 | w·m� | 6 |
177 | ²³� | 6 |
178 | σ� | 6 |
179 | “good� | 6 |
180 | ₀₀ | 6 |
181 | ₆₅b | 6 |
182 | ₋₂₄ | 6 |
183 | �-induced | 6 |
184 | �-k� | 6 |
185 | �/cd8� | 6 |
186 | �al | 6 |
187 | �cd56� | 6 |
188 | �cu-raft-rgd | 6 |
189 | �u | 6 |
190 | �¹� | 6 |
191 | -pi | 5 |
192 | -subunit | 5 |
193 | //www.chictr.org/en/proj/show.aspx | 5 |
194 | 10¹¹ | 5 |
195 | 1×10� | 5 |
196 | 2� | 5 |
197 | aβ₃� | 5 |
198 | be²� | 5 |
199 | bien | 5 |
200 | cr³� | 5 |
201 | cv� | 5 |
202 | c₂� | 5 |
203 | de� | 5 |
204 | dgemric-t� | 5 |
205 | fe� | 5 |
206 | gender-speci� | 5 |
207 | glcnac₂-pa | 5 |
208 | g·d� | 5 |
209 | g₀/g� | 5 |
210 | km·h� | 5 |
211 | low� | 5 |
212 | menc-crm� | 5 |
213 | o₂·� | 5 |
214 | pd-1� | 5 |
215 | r-ch� | 5 |
216 | rorγt� | 5 |
217 | rδ� | 5 |
218 | tm³� | 5 |
219 | transform-us | 5 |
220 | γ₂ | 5 |
221 | χ²� | 5 |
222 | ₈ | 5 |
223 | ₋� | 5 |
224 | �/k� | 5 |
225 | �cd16� | 5 |
226 | �cd25 | 5 |
227 | �cd25� | 5 |
228 | �day | 5 |
229 | �fe | 5 |
230 | �hctz | 5 |
231 | �mtc | 5 |
232 | �si | 5 |
233 | �¹tl | 5 |
234 | �¹² | 5 |
235 | -cf3ch� | 4 |
236 | //apps.who.int/trialsearch/trial.aspx | 4 |
237 | //public.ukcrn.org.uk/search/studydetail.aspx | 4 |
238 | 10¹� | 4 |
239 | =-0.32 | 4 |
240 | anti-tnf- | 4 |
241 | apob/lp-pla₂� | 4 |
242 | bene� | 4 |
243 | cance | 4 |
244 | cd16� | 4 |
245 | cd25� | 4 |
246 | chcho | 4 |
247 | ch� | 4 |
248 | cl� | 4 |
249 | ctla-4� | 4 |
250 | cum� | 4 |
251 | cx₃cr1� | 4 |
252 | decade� | 4 |
253 | emulsi� | 4 |
254 | esat� | 4 |
255 | foxp3� | 4 |
256 | g·kg� | 4 |
257 | hamd� | 4 |
258 | high� | 4 |
259 | hko� | 4 |
260 | hrsd� | 4 |
261 | h·ng� | 4 |
262 | h₃/h� | 4 |
263 | ifn� | 4 |
264 | ldlr� | 4 |
265 | liter� | 4 |
266 | ln³� | 4 |
267 | los150� | 4 |
268 | lt� | 4 |
269 | lys²� | 4 |
270 | m-b� | 4 |
271 | meq·l� | 4 |
272 | mg·dl� | 4 |
273 | mg·d� | 4 |
274 | ml·min� | 4 |
275 | mujer | 4 |
276 | nhxyn11� | 4 |
277 | nh� | 4 |
278 | nilavembu | 4 |
279 | ni²� | 4 |
280 | n·s� | 4 |
281 | order=1 | 4 |
282 | o₃₉ | 4 |
283 | pmol·l� | 4 |
284 | pmol� | 4 |
285 | pt� | 4 |
286 | rac·steer� | 4 |
287 | rb� | 4 |
288 | self� | 4 |
289 | sex� | 4 |
290 | sh� | 4 |
291 | star� | 4 |
292 | sterolq� | 4 |
293 | tb� | 4 |
294 | year� | 4 |
295 | α-pw� | 4 |
296 | δpost-fev� | 4 |
297 | δpre-fev� | 4 |
298 | ₀₆₋₃₂₄ | 4 |
299 | ₂₀ | 4 |
300 | ₂� | 4 |
301 | ₃.₈ | 4 |
302 | ₇fe₅₂ge� | 4 |
303 | �-codoped | 4 |
304 | �-evoked | 4 |
305 | �/a� | 4 |
306 | �/er³� | 4 |
307 | �/mc� | 4 |
308 | �/μl | 4 |
309 | �ca | 4 |
310 | �f-pet | 4 |
311 | �foxp3� | 4 |
312 | �gender | 4 |
313 | �gln | 4 |
314 | �hctz37.5 | 4 |
315 | �kg | 4 |
316 | �min | 4 |
317 | �ml | 4 |
318 | �²·min� | 4 |
319 | �³/ml | 4 |
320 | �¹·day� | 4 |
321 | �¹·ml� | 4 |
322 | �¹∙day� | 4 |
323 | -relaxivity | 3 |
324 | -xkxbio₃ | 3 |
325 | .₅te₃ | 3 |
326 | //clinicaltrials.gov/ct/show/nct00338260 | 3 |
327 | //upload.umin.ac.jp/cgi-open-bin/ctr/ctr.cgi | 3 |
328 | 1.8-m | 3 |
329 | 39� | 3 |
330 | 4a� | 3 |
331 | 7.5� | 3 |
332 | afg� | 3 |
333 | ag₃₂sg� | 3 |
334 | al� | 3 |
335 | am-treated | 3 |
336 | ampli� | 3 |
337 | and2 | 3 |
338 | aβ� | 3 |
339 | ba� | 3 |
340 | bi₀.₅sb� | 3 |
341 | bi₅ti₃feo� | 3 |
342 | cd103� | 3 |
343 | cd19� | 3 |
344 | cd1c� | 3 |
345 | cd27� | 3 |
346 | choh | 3 |
347 | choornam | 3 |
348 | cient | 3 |
349 | double� | 3 |
350 | drug-na� | 3 |
351 | dsm� | 3 |
352 | d₃� | 3 |
353 | ef� | 3 |
354 | ene | 3 |
355 | ep� | 3 |
356 | fuc� | 3 |
357 | function=brows | 3 |
358 | g/lb | 3 |
359 | hbt� | 3 |
360 | hg� | 3 |
361 | hit� | 3 |
362 | hplc-esi� | 3 |
363 | ii° | 3 |
364 | j� | 3 |
365 | litre� | 3 |
366 | los100� | 3 |
367 | m-units·m� | 3 |
368 | mass� | 3 |
369 | max� | 3 |
370 | mikimiki | 3 |
371 | m·s� | 3 |
372 | n-palmitoyl-fb� | 3 |
373 | ng·ml� | 3 |
374 | o-b | 3 |
375 | o-b� | 3 |
376 | p23� | 3 |
377 | p53� | 3 |
378 | ps19� | 3 |
379 | re-nhxyn11� | 3 |
380 | rf� | 3 |
381 | rg� | 3 |
382 | sec� | 3 |
383 | tau50 | 3 |
384 | tgfβ� | 3 |
385 | tim-3� | 3 |
386 | time� | 3 |
387 | u� | 3 |
388 | wmfev� | 3 |
389 | wm� | 3 |
390 | wt� | 3 |
391 | x³σg� | 3 |
392 | z-ho-ch� | 3 |
393 | zh� | 3 |
394 | zjaz | 3 |
395 | z� | 3 |
396 | β-k₂bi₈se� | 3 |
397 | δfev� | 3 |
398 | μg·kg� | 3 |
399 | μl/well | 3 |
400 | ν� | 3 |
401 | “at-risk� | 3 |
402 | “out-of-proportion� | 3 |
403 | ₃co₄ | 3 |
404 | ₄n� | 3 |
405 | ₉₂-sta� | 3 |
406 | ₋₃₅ | 3 |
407 | ₋₄₂ | 3 |
408 | �-activated | 3 |
409 | �-binding | 3 |
410 | �-dependent | 3 |
411 | �-hrms/ms | 3 |
412 | �-mg | 3 |
413 | �-yb³� | 3 |
414 | �/ml | 3 |
415 | �/nadh | 3 |
416 | �f-fluorodeoxyglucose | 3 |
417 | �ga-labeled | 3 |
418 | �ga-trap | 3 |
419 | �hctz25 | 3 |
420 | �k | 3 |
421 | �²¹ | 3 |
422 | �²•2 | 3 |
423 | �¹·min·� | 3 |
424 | �¹¹ | 3 |
425 | �¹•d� | 3 |
426 | �₅₀ | 3 |
427 | 'temu | 2 |
428 | +� | 2 |
429 | -226 | 2 |
430 | -auc₀₋� | 2 |
431 | -da1a | 2 |
432 | -och� | 2 |
433 | -xtixo₃ | 2 |
434 | //clinicaltrials.gov/ct2/results | 2 |
435 | //clinicaltrials.gov/ct2/show/nct00091962 | 2 |
436 | //diagnosticpathology.slidepath.com/dih/webviewer.php | 2 |
437 | //drks-neu.uniklinik-freiburg.de/drks_web/navigate.do | 2 |
438 | //taylorandfrancis.metapress.com/openurl.asp | 2 |
439 | //www.anzctr.org.au/registry/trial_review.aspx | 2 |
440 | //www.chictr.org/cn/proj/show.aspx | 2 |
441 | /10� | 2 |
442 | /� | 2 |
443 | 0→� | 2 |
444 | 1.0×10� | 2 |
445 | 100g� | 2 |
446 | 10^� | 2 |
447 | 15q2 | 2 |
448 | 2.9×10� | 2 |
449 | 274.9 | 2 |
450 | 3p2 | 2 |
451 | 4b� | 2 |
452 | 4c� | 2 |
453 | 5×10� | 2 |
454 | 7,904 | 2 |
455 | =-0.31 | 2 |
456 | =-0.43 | 2 |
457 | =0.191 | 2 |
458 | =0.658 | 2 |
459 | ag₃₂mpg� | 2 |
460 | al₅₉ti₂₆cr� | 2 |
461 | al₆₆ti₂₄cr� | 2 |
462 | and� | 2 |
463 | apoe� | 2 |
464 | arg³� | 2 |
465 | arz� | 2 |
466 | auc₀₋₄h | 2 |
467 | au₃� | 2 |
468 | b-c� | 2 |
469 | ba²� | 2 |
470 | bi₀.₉gd₀.� | 2 |
471 | bw� | 2 |
472 | car6� | 2 |
473 | cd11b� | 2 |
474 | cd133� | 2 |
475 | cd144� | 2 |
476 | cd163� | 2 |
477 | cd24� | 2 |
478 | cd31� | 2 |
479 | cd85j� | 2 |
480 | cd²� | 2 |
481 | ce₂o₄� | 2 |
482 | ce₃o₆� | 2 |
483 | chcf3 | 2 |
484 | clo₄� | 2 |
485 | c₂c� | 2 |
486 | databases� | 2 |
487 | days·week� | 2 |
488 | delta� | 2 |
489 | diet� | 2 |
490 | dopamine-d� | 2 |
491 | dr� | 2 |
492 | dyn·s·cm� | 2 |
493 | dy³� | 2 |
494 | d·wk� | 2 |
495 | d₂� | 2 |
496 | efb� | 2 |
497 | ega-li� | 2 |
498 | er� | 2 |
499 | fú | 2 |
500 | gd³� | 2 |
501 | genre=journal | 2 |
502 | glp1r� | 2 |
503 | glycolyl-u-¹� | 2 |
504 | g•kg� | 2 |
505 | high-mg²� | 2 |
506 | hoku | 2 |
507 | hr� | 2 |
508 | hspg2� | 2 |
509 | h·d� | 2 |
510 | h₃o� | 2 |
511 | insulin-na� | 2 |
512 | jak3� | 2 |
513 | ji� | 2 |
514 | kcal•mol� | 2 |
515 | kg·m� | 2 |
516 | kg₋� | 2 |
517 | lacalut | 2 |
518 | lag-3� | 2 |
519 | log₋� | 2 |
520 | mahg� | 2 |
521 | man₃xyl� | 2 |
522 | man� | 2 |
523 | mbq� | 2 |
524 | mg×kg� | 2 |
525 | ml.kg� | 2 |
526 | mm� | 2 |
527 | molecule� | 2 |
528 | mp2x� | 2 |
529 | mpp� | 2 |
530 | mt� | 2 |
531 | mu·m� | 2 |
532 | n-acyl-fb� | 2 |
533 | n-c₆h� | 2 |
534 | navigationid=trial.html | 2 |
535 | nazn� | 2 |
536 | ng� | 2 |
537 | nh₃/nh₄� | 2 |
538 | nh₄� | 2 |
539 | nization | 2 |
540 | nī | 2 |
541 | onoo� | 2 |
542 | outcomes� | 2 |
543 | o₂·kg� | 2 |
544 | pc₇� | 2 |
545 | pg� | 2 |
546 | phenyl-u-¹� | 2 |
547 | protein� | 2 |
548 | pro� | 2 |
549 | pr³� | 2 |
550 | qids-sr� | 2 |
551 | r1� | 2 |
552 | reps·min� | 2 |
553 | re³� | 2 |
554 | rmed | 2 |
555 | saludable | 2 |
556 | sankhy� | 2 |
557 | scienti� | 2 |
558 | shí | 2 |
559 | sp/nk� | 2 |
560 | stretch� | 2 |
561 | symptoms� | 2 |
562 | take10 | 2 |
563 | tc=2168 | 2 |
564 | tc=2297 | 2 |
565 | tc=3116 | 2 |
566 | term=rollman+cabg | 2 |
567 | tgenr-nad� | 2 |
568 | thr³� | 2 |
569 | tie2� | 2 |
570 | ti� | 2 |
571 | tnf-� | 2 |
572 | trans-cf3ch� | 2 |
573 | trans-chcl� | 2 |
574 | treatment-na� | 2 |
575 | trienyl | 2 |
576 | t₄/t� | 2 |
577 | t₈� | 2 |
578 | vol� | 2 |
579 | www.trialregister.nl/trialreg/admin/rctview.asp | 2 |
580 | xed | 2 |
581 | xi� | 2 |
582 | xyl� | 2 |
583 | x� | 2 |
584 | y₃ga₅o� | 2 |
585 | |� | 2 |
586 | ¡cuídate | 2 |
587 | µv� | 2 |
588 | α₄β₇� | 2 |
589 | γ� | 2 |
590 | δa₅� | 2 |
591 | η� | 2 |
592 | μg.kg� | 2 |
593 | μg� | 2 |
594 | μmol·kg� | 2 |
595 | μvk� | 2 |
596 | ер2 | 2 |
597 | “in-motion� | 2 |
598 | ₃³� | 2 |
599 | ₃� | 2 |
600 | ₅min | 2 |
601 | ₈₀ | 2 |
602 | ₉₂ | 2 |
603 | ₋₂₄-stimulated | 2 |
604 | ₋₃₅-induced | 2 |
605 | ₋₃₆₃ | 2 |
606 | ₋₄ | 2 |
607 | ≥10¹� | 2 |
608 | △� | 2 |
609 | �+mg²� | 2 |
610 | �-2-methyl-oxodienyl | 2 |
611 | �-3-keto | 2 |
612 | �-ala³� | 2 |
613 | �-doped | 2 |
614 | �-independent | 2 |
615 | �-mg²� | 2 |
616 | �-ocn | 2 |
617 | �-secreting | 2 |
618 | �/41� | 2 |
619 | �/cd34� | 2 |
620 | �/nkg2d� | 2 |
621 | �/s | 2 |
622 | �/u� | 2 |
623 | �/vegfr2� | 2 |
624 | �/yb³� | 2 |
625 | �/� | 2 |
626 | �be | 2 |
627 | �c-labeled | 2 |
628 | �cd4� | 2 |
629 | �cd8� | 2 |
630 | �co₂ | 2 |
631 | �d | 2 |
632 | �f-fdg | 2 |
633 | �f-fluoride | 2 |
634 | �f-nifrolidine | 2 |
635 | �f-nifzetidine | 2 |
636 | �ga-labeling | 2 |
637 | �h | 2 |
638 | �iams | 2 |
639 | �mg | 2 |
640 | �mtc-lp-cooh | 2 |
641 | �nanimal | 2 |
642 | �ndiet | 2 |
643 | �no | 2 |
644 | �or | 2 |
645 | �salmeterol | 2 |
646 | �si-nmr | 2 |
647 | �span | 2 |
648 | �¹.min� | 2 |
649 | �¹.m� | 2 |
650 | �¹/μu/ml | 2 |
651 | �¹·wk� | 2 |
652 | �¹∶120 | 2 |
653 | 'medline | 1 |
654 | +0.16x10� | 1 |
655 | +17×10� | 1 |
656 | +²h� | 1 |
657 | -0.01x10� | 1 |
658 | -0.56� | 1 |
659 | -0.69� | 1 |
660 | -0.91� | 1 |
661 | -2� | 1 |
662 | -983 | 1 |
663 | -actinin | 1 |
664 | -catenins | 1 |
665 | -dr� | 1 |
666 | -lactamases | 1 |
667 | -n� | 1 |
668 | -o� | 1 |
669 | -pka-nmda | 1 |
670 | -protocol | 1 |
671 | -relaxivities | 1 |
672 | -s₂ | 1 |
673 | -x₄ | 1 |
674 | -y113a | 1 |
675 | -� | 1 |
676 | .ultrasound | 1 |
677 | //apps.who.int/trialsearch/trial2.aspx | 1 |
678 | //clinicaltrials.gov/ct/show/nct00043758 | 1 |
679 | //clinicaltrials.gov/ct/show/nct00132743 | 1 |
680 | //clinicaltrials.gov/ct2/show/nct00088478 | 1 |
681 | //clinicaltrials.gov/ct2/show/nct00206310 | 1 |
682 | //clinicaltrials.gov/ct2/show/nct00338962 | 1 |
683 | //clinicaltrials.gov/ct2/show/nct00472862 | 1 |
684 | //clinicaltrials.gov/ct2/show/nct00501579 | 1 |
685 | //clinicaltrials.gov/ct2/show/nct00562627 | 1 |
686 | //clinicaltrials.gov/ct2/show/nct00609778 | 1 |
687 | //clinicaltrials.gov/ct2/show/nct00611286 | 1 |
688 | //clinicaltrials.gov/ct2/show/nct00693849 | 1 |
689 | //clinicaltrials.gov/ct2/show/nct00789243 | 1 |
690 | //clinicaltrials.gov/ct2/show/nct00789828 | 1 |
691 | //clinicaltrials.gov/ct2/show/nct00849043 | 1 |
692 | //clinicaltrials.gov/ct2/show/nct00863798 | 1 |
693 | //clinicaltrials.gov/ct2/show/nct01141608 | 1 |
694 | //clinicaltrials.gov/ct2/show/nct01154023 | 1 |
695 | //clinicaltrials.gov/ct2/show/nct01178008 | 1 |
696 | //clinicaltrials.gov/ct2/show/nct01201837 | 1 |
697 | //clinicaltrials.gov/ct2/show/nct01294761 | 1 |
698 | //clinicaltrials.gov/ct2/show/nct01361932 | 1 |
699 | //clinicaltrials.gov/ct2/show/nct01384656 | 1 |
700 | //clinicaltrials.gov/ct2/show/nct01386853 | 1 |
701 | //clinicaltrials.gov/ct2/show/nct01398488 | 1 |
702 | //clinicaltrials.gov/ct2/show/nct01447966 | 1 |
703 | //clinicaltrials.gov/ct2/show/nct01556763 | 1 |
704 | //clinicaltrials.gov/ct2/show/nct01880710 | 1 |
705 | //clinicaltrials.gov/ct2/show/nct02016079 | 1 |
706 | //e-irb.khmccri.or.kr/eirb/receipt/index.html | 1 |
707 | //education.amjmed.com/video.php | 1 |
708 | //elearning.facs.org/mod/resource/view.php | 1 |
709 | //hvpmalaysia.kk.usm.my/mhgvc/index.php | 1 |
710 | //mht.mis.nchu.edu.tw/moodle/course/view.php | 1 |
711 | //www.cancer.gov/search/viewclinicaltrials.aspx | 1 |
712 | //www.cct.cuhk.edu.hk/registry/publictrialrecord.aspx | 1 |
713 | //www.clinicaltrials.gov/ct/show/nct00114491 | 1 |
714 | //www.clinicaltrials.gov/ct/show/nct00174993 | 1 |
715 | //www.clinicaltrials.gov/ct/show/nct00344513 | 1 |
716 | //www.clinicaltrials.gov/ct2/results | 1 |
717 | //www.clinicaltrials.gov/ct2/show/nct00090324 | 1 |
718 | //www.clinicaltrials.gov/ct2/show/nct00106210 | 1 |
719 | //www.clinicaltrials.gov/ct2/show/nct00380731 | 1 |
720 | //www.clinicaltrials.gov/ct2/show/nct00449488 | 1 |
721 | //www.clinicaltrials.gov/ct2/show/nct00466193 | 1 |
722 | //www.clinicaltrials.gov/ct2/show/nct00540605 | 1 |
723 | //www.clinicaltrials.gov/ct2/show/nct00764868 | 1 |
724 | //www.clinicaltrials.gov/ct2/show/nct00772044 | 1 |
725 | //www.clinicaltrials.gov/ct2/show/nct00835003 | 1 |
726 | //www.clinicaltrials.gov/ct2/show/nct01952912 | 1 |
727 | //www.clinicaltrials.gov/ct2/show/nct02051426 | 1 |
728 | //www.controlled-trials.com/isrctn/search.html | 1 |
729 | //www.crd.york.ac.uk/prospero/display_record.asp | 1 |
730 | //www.hus.fi/ | 1 |
731 | //www.isrctn.com/isrctn39629189 | 1 |
732 | //www.moh.gov.sg/mohcorp/publications.aspx | 1 |
733 | //www.ncbi.nlm.nih.gov/geo/query/acc.cgi | 1 |
734 | //www.pactr.org/atmweb/appmanager/atm/atmregistry | 1 |
735 | /arginine | 1 |
736 | /c� | 1 |
737 | /il10� | 1 |
738 | /k� | 1 |
739 | /mt₂ | 1 |
740 | /t� | 1 |
741 | /μ | 1 |
742 | /₃nb₂/₃ | 1 |
743 | 0.06mmoll� | 1 |
744 | 0.0� | 1 |
745 | 0.41� | 1 |
746 | 0.4±185.7 | 1 |
747 | 0.51–0.62 | 1 |
748 | 0.5×10� | 1 |
749 | 0.6±1.8 | 1 |
750 | 0.8mmoll� | 1 |
751 | 0.92+0.38 | 1 |
752 | 1-¹� | 1 |
753 | 1.10-5.28 | 1 |
754 | 1.2±0.5×10-3 | 1 |
755 | 1.2×10¹� | 1 |
756 | 1.3×10� | 1 |
757 | 1.96×10� | 1 |
758 | 10.2×10� | 1 |
759 | 100×10� | 1 |
760 | 10¹² | 1 |
761 | 14-ring | 1 |
762 | 150×10� | 1 |
763 | 15·l·min� | 1 |
764 | 15� | 1 |
765 | 16-21� | 1 |
766 | 182.2/10� | 1 |
767 | 1d=450 | 1 |
768 | 1g/m2/h | 1 |
769 | 2.13×10� | 1 |
770 | 2.8±0.3mlmin₋� | 1 |
771 | 2.9±3.9 | 1 |
772 | 2000� | 1 |
773 | 20� | 1 |
774 | 23.5� | 1 |
775 | 25×10� | 1 |
776 | 27.8±12.4 | 1 |
777 | 3-o-linoleoyl-fb� | 1 |
778 | 3-o-oleoyl-fb� | 1 |
779 | 3-o-palmitoyl-fb� | 1 |
780 | 3.5×10� | 1 |
781 | 3.9±0.5mlmin₋� | 1 |
782 | 3.9×10¹� | 1 |
783 | 30-80×10� | 1 |
784 | 30×10� | 1 |
785 | 30� | 1 |
786 | 31.0� | 1 |
787 | 31.8� | 1 |
788 | 36� | 1 |
789 | 38� | 1 |
790 | 3x10� | 1 |
791 | 3×10� | 1 |
792 | 4.3134-0.0162 | 1 |
793 | 4.5g� | 1 |
794 | 4x10� | 1 |
795 | 5-o-linoleoyl-fb� | 1 |
796 | 5-o-oleoyl-fb� | 1 |
797 | 5-o-palmitoyl-fb� | 1 |
798 | 5.0×10� | 1 |
799 | 5.1×10� | 1 |
800 | 5.6×10¹� | 1 |
801 | 5.90×10� | 1 |
802 | 50-100×10� | 1 |
803 | 50×10� | 1 |
804 | 6.2� | 1 |
805 | 6.33×10� | 1 |
806 | 6.3640-0.0316 | 1 |
807 | 6.4� | 1 |
808 | 6.6� | 1 |
809 | 6.9� | 1 |
810 | 60.3±54.1 | 1 |
811 | 8.4×10� | 1 |
812 | 80×10� | 1 |
813 | 9.8×10� | 1 |
814 | 9� | 1 |
815 | :3.24±0.41 | 1 |
816 | :3.72±0.19 | 1 |
817 | =-.58 | 1 |
818 | =-.82 | 1 |
819 | =-.89 | 1 |
820 | =-0.143 | 1 |
821 | =-0.159 | 1 |
822 | =-0.182 | 1 |
823 | =-0.207 | 1 |
824 | =-0.217 | 1 |
825 | =-0.230 | 1 |
826 | =-0.295 | 1 |
827 | =-0.389 | 1 |
828 | =-0.491 | 1 |
829 | =-0.61 | 1 |
830 | =-0.610 | 1 |
831 | =-0.65 | 1 |
832 | =-0.716 | 1 |
833 | =-0.740 | 1 |
834 | =-0.771 | 1 |
835 | =-0·73 | 1 |
836 | =-0·74 | 1 |
837 | =0.019 | 1 |
838 | =0.061 | 1 |
839 | =0.207 | 1 |
840 | =0.224 | 1 |
841 | =0.332 | 1 |
842 | =0.379 | 1 |
843 | =0.40-0.62 | 1 |
844 | =0.502 | 1 |
845 | =0.556 | 1 |
846 | =0.58-0.80 | 1 |
847 | =0.603 | 1 |
848 | =0.628 | 1 |
849 | =0.638 | 1 |
850 | =0.677 | 1 |
851 | =0.680 | 1 |
852 | =0.91-0.96 | 1 |
853 | =0·73 | 1 |
854 | =5.35 | 1 |
855 | =8660kg | 1 |
856 | _nfpb=true | 1 |
857 | `id | 1 |
858 | abts•� | 1 |
859 | ab� | 1 |
860 | acc=gse38942 | 1 |
861 | acetaminophen� | 1 |
862 | action� | 1 |
863 | actrn=12609000885291 | 1 |
864 | actrn=12611000081910 | 1 |
865 | actrn=12611000929909 | 1 |
866 | actrn=12611000951954 | 1 |
867 | actrn=12612000132842 | 1 |
868 | acyw� | 1 |
869 | adrian | 1 |
870 | ads₃×s³×t� | 1 |
871 | aging.� | 1 |
872 | ala³� | 1 |
873 | alcohol� | 1 |
874 | alk� | 1 |
875 | alpha2c-ar | 1 |
876 | amico | 1 |
877 | antagonist/h� | 1 |
878 | anteiso-c� | 1 |
879 | anti� | 1 |
880 | aom/il10� | 1 |
881 | apj� | 1 |
882 | appraisal� | 1 |
883 | arbs-at� | 1 |
884 | arthritis� | 1 |
885 | asenapine-n� | 1 |
886 | asp²� | 1 |
887 | assessment� | 1 |
888 | ataxia� | 1 |
889 | atheism | 1 |
890 | attitudes� | 1 |
891 | audadis� | 1 |
892 | aw� | 1 |
893 | a₀ | 1 |
894 | b/angiotensin | 1 |
895 | background� | 1 |
896 | baclo₄� | 1 |
897 | beat� | 1 |
898 | ben� | 1 |
899 | beta-lactams� | 1 |
900 | between� | 1 |
901 | bf₄� | 1 |
902 | bia� | 1 |
903 | bifida� | 1 |
904 | bisul� | 1 |
905 | bi₃.₆eu₀.₄ti₃o� | 1 |
906 | blicket | 1 |
907 | blt� | 1 |
908 | bolites | 1 |
909 | bound� | 1 |
910 | brain� | 1 |
911 | breaths·min� | 1 |
912 | brinolytic | 1 |
913 | broblasts | 1 |
914 | brosis | 1 |
915 | c-n-r | 1 |
916 | c6� | 1 |
917 | cab� | 1 |
918 | carakasamhit� | 1 |
919 | cardean™ | 1 |
920 | cases/10� | 1 |
921 | catenatum+0.75×10� | 1 |
922 | ccr7� | 1 |
923 | cd11c� | 1 |
924 | cd138� | 1 |
925 | cd14+cd16� | 1 |
926 | cd34� | 1 |
927 | cd39� | 1 |
928 | cd45ro� | 1 |
929 | cd68� | 1 |
930 | cdrid=68869 | 1 |
931 | ce₀.₇y₀.� | 1 |
932 | ce₂o₃d� | 1 |
933 | ce₃o₅d₂� | 1 |
934 | cf3cf� | 1 |
935 | ch-ch | 1 |
936 | chu� | 1 |
937 | ciency | 1 |
938 | citabine | 1 |
939 | clairage | 1 |
940 | clstn3� | 1 |
941 | code=02 | 1 |
942 | coenzymeq� | 1 |
943 | comet� | 1 |
944 | costs'� | 1 |
945 | co³� | 1 |
946 | co₃²� | 1 |
947 | co� | 1 |
948 | cpα� | 1 |
949 | cross� | 1 |
950 | cr₂o₇²� | 1 |
951 | cs� | 1 |
952 | ct2/show/nct00528515 | 1 |
953 | ct2/show/nct00931463 | 1 |
954 | c¹� | 1 |
955 | c₃� | 1 |
956 | d'e� | 1 |
957 | d-cd1c� | 1 |
958 | d3-c� | 1 |
959 | dazzled | 1 |
960 | df/emtri | 1 |
961 | dhy� | 1 |
962 | dh� | 1 |
963 | difference517 | 1 |
964 | difference551 | 1 |
965 | difference56 | 1 |
966 | disease.� | 1 |
967 | disorders� | 1 |
968 | doi=363175 | 1 |
969 | dpph� | 1 |
970 | dugdh� | 1 |
971 | dx� | 1 |
972 | dødelige | 1 |
973 | dγ∕d� | 1 |
974 | e/e� | 1 |
975 | ees=0.91 | 1 |
976 | enchondroma | 1 |
977 | endothelin-1� | 1 |
978 | esi� | 1 |
979 | eucharist | 1 |
980 | eurekalert | 1 |
981 | event_id=445 | 1 |
982 | events·h� | 1 |
983 | event� | 1 |
984 | ević | 1 |
985 | exercise� | 1 |
986 | experimenter� | 1 |
987 | ex� | 1 |
988 | fa/ | 1 |
989 | factor-β� | 1 |
990 | factor-� | 1 |
991 | false� | 1 |
992 | family� | 1 |
993 | fast-food/burgers | 1 |
994 | fg� | 1 |
995 | fiury | 1 |
996 | follow� | 1 |
997 | forum/wikipathways-devel | 1 |
998 | forum/wikipathways-discuss | 1 |
999 | ga� | 1 |
1000 | gensh� | 1 |
1001 | gfp� | 1 |
1002 | glu¹� | 1 |
1003 | glu� | 1 |
1004 | gly³� | 1 |
1005 | good/good/fair/poor | 1 |
1006 | growed | 1 |
1007 | gure-of-8-shaped | 1 |
1008 | haku | 1 |
1009 | hemoglobin/g | 1 |
1010 | her-2� | 1 |
1011 | hid� | 1 |
1012 | his� | 1 |
1013 | hiy� | 1 |
1014 | hla-b� | 1 |
1015 | honzou | 1 |
1016 | hours� | 1 |
1017 | hu� | 1 |
1018 | həli | 1 |
1019 | h₂cit� | 1 |
1020 | h₂₉n₃o₂ | 1 |
1021 | i4� | 1 |
1022 | ibdv-speci� | 1 |
1023 | id=25178 | 1 |
1024 | id=308008 | 1 |
1025 | id=308074 | 1 |
1026 | id=335115 | 1 |
1027 | id=335135 | 1 |
1028 | id=335159 | 1 |
1029 | id=335162 | 1 |
1030 | id=335463 | 1 |
1031 | id=335613 | 1 |
1032 | id=335931 | 1 |
1033 | id=336143 | 1 |
1034 | id=343019 | 1 |
1035 | id=343384 | 1 |
1036 | id=347799 | 1 |
1037 | id=347879 | 1 |
1038 | id=362005 | 1 |
1039 | id=362489 | 1 |
1040 | id=362949 | 1 |
1041 | id=7 | 1 |
1042 | id=81688 | 1 |
1043 | id=81803 | 1 |
1044 | id=82159 | 1 |
1045 | id=82509 | 1 |
1046 | id=82878 | 1 |
1047 | id=82978 | 1 |
1048 | id=83071 | 1 |
1049 | id=83667 | 1 |
1050 | id=crd42011001468 | 1 |
1051 | id=crd42013004364 | 1 |
1052 | id=register | 1 |
1053 | identified� | 1 |
1054 | ih� | 1 |
1055 | il-4� | 1 |
1056 | insufflation� | 1 |
1057 | interview� | 1 |
1058 | intimacy� | 1 |
1059 | in� | 1 |
1060 | ip₃-ca²� | 1 |
1061 | irbp� | 1 |
1062 | ischemia-modi� | 1 |
1063 | iso-c� | 1 |
1064 | jué | 1 |
1065 | kaku | 1 |
1066 | kamp� | 1 |
1067 | kcal·kg� | 1 |
1068 | kermak | 1 |
1069 | kg.m� | 1 |
1070 | kg/1.7 | 1 |
1071 | kg•m� | 1 |
1072 | king� | 1 |
1073 | kir2dl1/s1� | 1 |
1074 | know.� | 1 |
1075 | komeri� | 1 |
1076 | kom� | 1 |
1077 | kulliyy� | 1 |
1078 | ku� | 1 |
1079 | kv·m� | 1 |
1080 | k₂� | 1 |
1081 | l.min� | 1 |
1082 | laboratory� | 1 |
1083 | large� | 1 |
1084 | la₃ga₅sio� | 1 |
1085 | legibly | 1 |
1086 | lessons� | 1 |
1087 | life'� | 1 |
1088 | lifestyle/mind | 1 |
1089 | likelihood� | 1 |
1090 | li� | 1 |
1091 | losartan-at� | 1 |
1092 | lozano | 1 |
1093 | ltration | 1 |
1094 | lu/10� | 1 |
1095 | lvarez | 1 |
1096 | lys³� | 1 |
1097 | l₅-s� | 1 |
1098 | mag� | 1 |
1099 | malaky� | 1 |
1100 | man₂xyl� | 1 |
1101 | maq� | 1 |
1102 | mc� | 1 |
1103 | methyl-¹� | 1 |
1104 | methylation-speci� | 1 |
1105 | met¹²� | 1 |
1106 | met¹� | 1 |
1107 | mgkg� | 1 |
1108 | mg·ml� | 1 |
1109 | mg·steer� | 1 |
1110 | mg•kg� | 1 |
1111 | micromol·l� | 1 |
1112 | mins.wk� | 1 |
1113 | minute� | 1 |
1114 | min·session� | 1 |
1115 | mirtazapine–first� | 1 |
1116 | mirtazapine� | 1 |
1117 | mitogen� | 1 |
1118 | mi� | 1 |
1119 | mj� | 1 |
1120 | ml.min� | 1 |
1121 | ml·yr� | 1 |
1122 | mmol.l� | 1 |
1123 | mmol·kg� | 1 |
1124 | mmol·min·l� | 1 |
1125 | mmp� | 1 |
1126 | mnbr₄²� | 1 |
1127 | mncl₄²� | 1 |
1128 | mnx₄²� | 1 |
1129 | model� | 1 |
1130 | modi� | 1 |
1131 | monoene | 1 |
1132 | monoenyl | 1 |
1133 | month� | 1 |
1134 | morphology� | 1 |
1135 | mosm.kg� | 1 |
1136 | mosmol·kg� | 1 |
1137 | mosm·kg� | 1 |
1138 | mpowered | 1 |
1139 | ms� | 1 |
1140 | mutants/10� | 1 |
1141 | mu·min·l� | 1 |
1142 | mu� | 1 |
1143 | n-linoleoyl-fb� | 1 |
1144 | n-oleoyl-fb� | 1 |
1145 | nakanda | 1 |
1146 | nau/whakapapa | 1 |
1147 | nct00376571 | 1 |
1148 | nct00643760 | 1 |
1149 | nc� | 1 |
1150 | ndex | 1 |
1151 | ndice | 1 |
1152 | nicu-bazr₀.� | 1 |
1153 | non� | 1 |
1154 | ntf₂� | 1 |
1155 | n·kg� | 1 |
1156 | n₂� | 1 |
1157 | o-acyl-fb� | 1 |
1158 | observer� | 1 |
1159 | oh� | 1 |
1160 | on� | 1 |
1161 | open� | 1 |
1162 | order=1cp | 1 |
1163 | order_1 | 1 |
1164 | ori/non-pacific | 1 |
1165 | otf� | 1 |
1166 | outcasts | 1 |
1167 | o₂•� | 1 |
1168 | o₃₋δ | 1 |
1169 | p,0 | 1 |
1170 | p.met1 | 1 |
1171 | p=1.1´10� | 1 |
1172 | p=1.3×10� | 1 |
1173 | p=2.9´10� | 1 |
1174 | p=5.2´10� | 1 |
1175 | p=6.9´10� | 1 |
1176 | participant-witnesses | 1 |
1177 | path=1 | 1 |
1178 | patients� | 1 |
1179 | pd� | 1 |
1180 | people-m� | 1 |
1181 | pf₆� | 1 |
1182 | phase� | 1 |
1183 | phn� | 1 |
1184 | placebo� | 1 |
1185 | population� | 1 |
1186 | posadzki | 1 |
1187 | possible.� | 1 |
1188 | prede� | 1 |
1189 | preschool-si | 1 |
1190 | prespeci� | 1 |
1191 | proj=1618 | 1 |
1192 | proj=2132 | 1 |
1193 | proj=2384 | 1 |
1194 | proj=2561 | 1 |
1195 | proj=3486 | 1 |
1196 | proj=3820 | 1 |
1197 | proj=3904 | 1 |
1198 | protezama | 1 |
1199 | pvp-ag� | 1 |
1200 | py3 | 1 |
1201 | q=39629189 | 1 |
1202 | qaw� | 1 |
1203 | qìg� | 1 |
1204 | r-blocking | 1 |
1205 | range� | 1 |
1206 | re=v*d*� | 1 |
1207 | recognition� | 1 |
1208 | refused� | 1 |
1209 | regularly� | 1 |
1210 | rehabilitationsverfahren | 1 |
1211 | reviews� | 1 |
1212 | rh� | 1 |
1213 | risk� | 1 |
1214 | rjuna | 1 |
1215 | ros1� | 1 |
1216 | ruih� | 1 |
1217 | rydberg� | 1 |
1218 | ryū | 1 |
1219 | ry� | 1 |
1220 | s/cm� | 1 |
1221 | s1� | 1 |
1222 | saffron.� | 1 |
1223 | sam� | 1 |
1224 | sb-c� | 1 |
1225 | schedule� | 1 |
1226 | seis� | 1 |
1227 | ser¹¹� | 1 |
1228 | seven� | 1 |
1229 | sfcs/10� | 1 |
1230 | shu� | 1 |
1231 | single-object | 1 |
1232 | single� | 1 |
1233 | slr� | 1 |
1234 | sl� | 1 |
1235 | snapshotid=13617947952577 | 1 |
1236 | snapshotid=13617948230017 | 1 |
1237 | sn� | 1 |
1238 | solid� | 1 |
1239 | spreaded | 1 |
1240 | srch=isrctn84130388 | 1 |
1241 | sst� | 1 |
1242 | standard� | 1 |
1243 | sta� | 1 |
1244 | steer� | 1 |
1245 | studyid=10479 | 1 |
1246 | studyid=13538 | 1 |
1247 | studyid=4058 | 1 |
1248 | studyid=7285 | 1 |
1249 | stufenverfahren | 1 |
1250 | sub-g� | 1 |
1251 | sure.� | 1 |
1252 | suvmax� | 1 |
1253 | syndrome� | 1 |
1254 | tae-j� | 1 |
1255 | tb³� | 1 |
1256 | tc=1123 | 1 |
1257 | tc=1155 | 1 |
1258 | tc=1351 | 1 |
1259 | tc=1576 | 1 |
1260 | tc=1639 | 1 |
1261 | tc=1696 | 1 |
1262 | tc=1786 | 1 |
1263 | tc=1836 | 1 |
1264 | tc=1867 | 1 |
1265 | tc=1892 | 1 |
1266 | tc=2018 | 1 |
1267 | tc=2058 | 1 |
1268 | tc=2126 | 1 |
1269 | tc=2233 | 1 |
1270 | tc=2303 | 1 |
1271 | tc=2584 | 1 |
1272 | tc=2665 | 1 |
1273 | tc=2922 | 1 |
1274 | tc=2993 | 1 |
1275 | tc=3007 | 1 |
1276 | tc=3045 | 1 |
1277 | tc=3102 | 1 |
1278 | tc=3147 | 1 |
1279 | tc=3288 | 1 |
1280 | tc=3377 | 1 |
1281 | tc=3396 | 1 |
1282 | tc=3596 | 1 |
1283 | tc=4169 | 1 |
1284 | tc=467 | 1 |
1285 | tc=703 | 1 |
1286 | tc=820 | 1 |
1287 | tc=854 | 1 |
1288 | temperature.� | 1 |
1289 | term=00863798 | 1 |
1290 | term=behavioral+intervention+for+insomnia+in+older+adults | 1 |
1291 | term=cer-001 | 1 |
1292 | term=corona | 1 |
1293 | term=desipramine+and+alcohol+dependence+and+depression | 1 |
1294 | term=exist-1 | 1 |
1295 | term=gik+and+opcab | 1 |
1296 | term=gottlieb+tablet+pc+education | 1 |
1297 | term=hysterectomy | 1 |
1298 | term=international+study+to+predict+optimized+treatment+for+depression | 1 |
1299 | term=linc | 1 |
1300 | term=mauritius | 1 |
1301 | term=mtn-002 | 1 |
1302 | term=nct00371176 | 1 |
1303 | term=nct00789243 | 1 |
1304 | term=nct00835003 | 1 |
1305 | term=nct01157416 | 1 |
1306 | term=nct01157429 | 1 |
1307 | term=nct01361932 | 1 |
1308 | term=nct01386853 | 1 |
1309 | term=nct01556763 | 1 |
1310 | term=nct016301952912 | 1 |
1311 | term=nct02051426 | 1 |
1312 | term=neurocom | 1 |
1313 | term=ocd+and+st+petersburg | 1 |
1314 | term=olanzapine+depot | 1 |
1315 | term=opal-hiv-1001 | 1 |
1316 | term=postpartum+acupuncture | 1 |
1317 | term=prodigy | 1 |
1318 | term=quetiapine+112 | 1 |
1319 | term=sirion | 1 |
1320 | term=social+anxiety+cognitive+behavioral+therapy+stanford | 1 |
1321 | term=spare | 1 |
1322 | term=spd489-306 | 1 |
1323 | term=spreng | 1 |
1324 | term=stimulant+reduction+intervention+using+dosed+exercise | 1 |
1325 | term=ventus | 1 |
1326 | term=ventus+medical | 1 |
1327 | term=voors | 1 |
1328 | tgf� | 1 |
1329 | three� | 1 |
1330 | tissue� | 1 |
1331 | tk� | 1 |
1332 | trialid=actrn12610000257066 | 1 |
1333 | trialid=actrn12610000958088 | 1 |
1334 | trialid=actrn12611001256965 | 1 |
1335 | trialid=cuhk_cct00037 | 1 |
1336 | trialid=drks00003322 | 1 |
1337 | trialid=ntr1862 | 1 |
1338 | two� | 1 |
1339 | t₂₂� | 1 |
1340 | t₅-t� | 1 |
1341 | t₉-l� | 1 |
1342 | u-¹� | 1 |
1343 | ugml� | 1 |
1344 | uncombinable | 1 |
1345 | use.� | 1 |
1346 | u·mg� | 1 |
1347 | v.cm� | 1 |
1348 | vef� | 1 |
1349 | ventilator� | 1 |
1350 | weight� | 1 |
1351 | whether/how | 1 |
1352 | whom.� | 1 |
1353 | wh� | 1 |
1354 | wild� | 1 |
1355 | wissenschaftlicher | 1 |
1356 | www.anzctr.org.au/trial_view.aspx | 1 |
1357 | www.clinicaltrials.gov/ct/show/nct00194454 | 1 |
1358 | www.clinicaltrials.gov/ct2/results | 1 |
1359 | www.crd.york.ac.uk/prospero/display_record.asp | 1 |
1360 | www.karger.com/ | 1 |
1361 | w·min� | 1 |
1362 | x³b� | 1 |
1363 | xī | 1 |
1364 | y=5.873×10� | 1 |
1365 | yana-s | 1 |
1366 | yat | 1 |
1367 | yb₀.� | 1 |
1368 | y³� | 1 |
1369 | y� | 1 |
1370 | zebra� | 1 |
1371 | zhèngz� | 1 |
1372 | |midi | 1 |
1373 | � | 1 |
1374 | ²-p2� | 1 |
1375 | ²h-³¹p₃� | 1 |
1376 | ²h-³¹p� | 1 |
1377 | ²h� | 1 |
1378 | µg·ml� | 1 |
1379 | µm/10� | 1 |
1380 | µmol·l� | 1 |
1381 | ·min� | 1 |
1382 | ·pro·� | 1 |
1383 | ×10-3 | 1 |
1384 | ×min� | 1 |
1385 | †| 1 |
1386 | å³.°c� | 1 |
1387 | ín | 1 |
1388 | β-amyloid� | 1 |
1389 | β₂γ | 1 |
1390 | θd� | 1 |
1391 | κoλλυ� | 1 |
1392 | κ� | 1 |
1393 | μg·l� | 1 |
1394 | μg×kg� | 1 |
1395 | μmol·g� | 1 |
1396 | μmol·min� | 1 |
1397 | μmol∙h∙l� | 1 |
1398 | π� | 1 |
1399 | ω� | 1 |
1400 | о₂greater | 1 |
1401 | рм� | 1 |
1402 | с� | 1 |
1403 | ṣid | 1 |
1404 | “aces� | 1 |
1405 | “aminals� | 1 |
1406 | “cracking� | 1 |
1407 | “disorganization� | 1 |
1408 | “early� | 1 |
1409 | “efficiency� | 1 |
1410 | “exercise� | 1 |
1411 | “experience� | 1 |
1412 | “fair� | 1 |
1413 | “fingerprinting� | 1 |
1414 | “high� | 1 |
1415 | “hospice� | 1 |
1416 | “infection | 1 |
1417 | “luxury.� | 1 |
1418 | “myelomeningocele | 1 |
1419 | “normalization� | 1 |
1420 | “opioid� | 1 |
1421 | “palliative� | 1 |
1422 | “patient-specific� | 1 |
1423 | “pleasant.� | 1 |
1424 | “pleasant� | 1 |
1425 | “preactivated� | 1 |
1426 | “program� | 1 |
1427 | “proper� | 1 |
1428 | “real-world� | 1 |
1429 | “regular� | 1 |
1430 | “soft-option� | 1 |
1431 | “sport� | 1 |
1432 | “stable� | 1 |
1433 | “statins� | 1 |
1434 | “thin� | 1 |
1435 | “training� | 1 |
1436 | “unclear� | 1 |
1437 | “unclosed� | 1 |
1438 | “unpleasant� | 1 |
1439 | ₀/d | 1 |
1440 | ₀/grams | 1 |
1441 | ₀copies/ml | 1 |
1442 | ₀iu/ml | 1 |
1443 | ₀₀c | 1 |
1444 | ₀₋� | 1 |
1445 | ₂-adp | 1 |
1446 | ₂-dependent | 1 |
1447 | ₂h� | 1 |
1448 | ₃- | 1 |
1449 | ₃-type | 1 |
1450 | ₃f | 1 |
1451 | ₃²� | 1 |
1452 | ₄and | 1 |
1453 | ₄₂ | 1 |
1454 | ₄� | 1 |
1455 | ₅=18.33 | 1 |
1456 | ₆-c₂₂ | 1 |
1457 | ₆-labeled | 1 |
1458 | ₆h₉o7 | 1 |
1459 | ₆₈ | 1 |
1460 | ₈-column | 1 |
1461 | ₈.₂ | 1 |
1462 | ₈h₂o | 1 |
1463 | ₈h₂₉o₂· | 1 |
1464 | ₉-c₂₃ | 1 |
1465 | ₉₂g | 1 |
1466 | ₉� | 1 |
1467 | ₋₂₀ | 1 |
1468 | ₋₃ | 1 |
1469 | ₋₃/dp | 1 |
1470 | ₋₄-subunits | 1 |
1471 | ₋₄₀ | 1 |
1472 | →0 | 1 |
1473 | →cc | 1 |
1474 | →²f₇/₂ | 1 |
1475 | ⇒� | 1 |
1476 | ∇� | 1 |
1477 | ∠o� | 1 |
1478 | ∼10� | 1 |
1479 | ∼c� | 1 |
1480 | ≈10� | 1 |
1481 | ≤1.3×10� | 1 |
1482 | ≤125×10� | 1 |
1483 | ≥.56 | 1 |
1484 | ≥10� | 1 |
1485 | 大黃附� | 1 |
1486 | 妇� | 1 |
1487 | 平� | 1 |
1488 | 春胶囊 | 1 |
1489 | 湯 | 1 |
1490 | 潜阳 | 1 |
1491 | 瘀胶囊 | 1 |
1492 | 血府� | 1 |
1493 | �- | 1 |
1494 | �-17� | 1 |
1495 | �-33� | 1 |
1496 | �-39� | 1 |
1497 | �-alkylguanine | 1 |
1498 | �-aminopropylspermine | 1 |
1499 | �-benzyladenine-type | 1 |
1500 | �-conducting | 1 |
1501 | �-cp₃o₆ | 1 |
1502 | �-depleted | 1 |
1503 | �-encoding | 1 |
1504 | �-glucuronide | 1 |
1505 | �-gly³� | 1 |
1506 | �-iminodiacetic | 1 |
1507 | �-influx | 1 |
1508 | �-ions | 1 |
1509 | �-linked | 1 |
1510 | �-modes | 1 |
1511 | �-ms/ms | 1 |
1512 | �-osteocalcin | 1 |
1513 | �-permeable | 1 |
1514 | �-related | 1 |
1515 | �-sensor | 1 |
1516 | �-ser³� | 1 |
1517 | �-tb³� | 1 |
1518 | �-tetrahydrocannabinol/thc | 1 |
1519 | �-thc-induced | 1 |
1520 | �-triggered | 1 |
1521 | �-urea | 1 |
1522 | �-wo₃ | 1 |
1523 | �.� | 1 |
1524 | �/c-kit� | 1 |
1525 | �/calmodulin-kinase | 1 |
1526 | �/ca²� | 1 |
1527 | �/cd16� | 1 |
1528 | �/cd1a� | 1 |
1529 | �/cd3� | 1 |
1530 | �/d-glucose | 1 |
1531 | �/fe²� | 1 |
1532 | �/hcit²� | 1 |
1533 | �/ho³� | 1 |
1534 | �/h₃o� | 1 |
1535 | �/kir2dl2/l3/s2� | 1 |
1536 | �/l-5.8 | 1 |
1537 | �/mnx₄²� | 1 |
1538 | �/m² | 1 |
1539 | �/sca1� | 1 |
1540 | �/taurocholate | 1 |
1541 | �/tio₂ | 1 |
1542 | �/tm³� | 1 |
1543 | �10 | 1 |
1544 | �15 | 1 |
1545 | �20 | 1 |
1546 | �2001 | 1 |
1547 | �30 | 1 |
1548 | �5 | 1 |
1549 | �5201 | 1 |
1550 | �=0.05 | 1 |
1551 | �atpase | 1 |
1552 | �c-urea | 1 |
1553 | �cd127 | 1 |
1554 | �cd24� | 1 |
1555 | �cfu | 1 |
1556 | �cfu/animal/day | 1 |
1557 | �cm2 | 1 |
1558 | �codeine | 1 |
1559 | �cu-labeled | 1 |
1560 | �d-child | 1 |
1561 | �dha | 1 |
1562 | �d₀ | 1 |
1563 | �elders | 1 |
1564 | �f-fluoro-2-deoxy-d-glucose | 1 |
1565 | �f-fluorodeoxy-glucose | 1 |
1566 | �f-fluorodeoxyglucose-pet | 1 |
1567 | �f-fluorodeoxyglucose-positron | 1 |
1568 | �f-galacto-rgd | 1 |
1569 | �f-nifene | 1 |
1570 | �f-nmr | 1 |
1571 | �f9/2 | 1 |
1572 | �fdg | 1 |
1573 | �fdg-pet | 1 |
1574 | �fluoro-deoxyglucose | 1 |
1575 | �f₄ | 1 |
1576 | �g/g | 1 |
1577 | �g/ml | 1 |
1578 | �ga-nodaga-c | 1 |
1579 | �ga-radiopharmaceuticals | 1 |
1580 | �gr-1� | 1 |
1581 | �homeostasis | 1 |
1582 | �i-echistatin | 1 |
1583 | �i-f-hbsag | 1 |
1584 | �i-h-hbsag | 1 |
1585 | �i-radiolabeled | 1 |
1586 | �i-ttr | 1 |
1587 | �i15/2 | 1 |
1588 | �itching | 1 |
1589 | �i₈ | 1 |
1590 | �kg� | 1 |
1591 | �m | 1 |
1592 | �management | 1 |
1593 | �mdc-ra | 1 |
1594 | �mnps | 1 |
1595 | �mobilization | 1 |
1596 | �mtc-sestamibi | 1 |
1597 | �n-enrichment | 1 |
1598 | �na | 1 |
1599 | �n₂ | 1 |
1600 | �p*l | 1 |
1601 | �point | 1 |
1602 | �reviewed� | 1 |
1603 | �s3/2 | 1 |
1604 | �selected | 1 |
1605 | �s₂ | 1 |
1606 | �t | 1 |
1607 | �t-cell | 1 |
1608 | �t/cd8� | 1 |
1609 | �tc-extametazime-labeled | 1 |
1610 | �total | 1 |
1611 | �t₂ | 1 |
1612 | �t� | 1 |
1613 | �week | 1 |
1614 | �x+17075.659 | 1 |
1615 | �²-12.2×10� | 1 |
1616 | �²-9.7×10� | 1 |
1617 | �²ca | 1 |
1618 | �²³ | 1 |
1619 | �²� | 1 |
1620 | �³ca | 1 |
1621 | �³eseekawqklcsl¹� | 1 |
1622 | �³sm | 1 |
1623 | �³₃system | 1 |
1624 | �¹.day� | 1 |
1625 | �¹dhs | 1 |
1626 | �¹h� | 1 |
1627 | �¹l | 1 |
1628 | �¹min� | 1 |
1629 | �¹pmol� | 1 |
1630 | �¹sec� | 1 |
1631 | �¹thallium | 1 |
1632 | �¹×d� | 1 |
1633 | �¹×h� | 1 |
1634 | �π | 1 |
1635 | �• | 1 |
1636 | �₅₀-value | 1 |
1637 | �₋yb³� | 1 |
1 | 'medline | 1 |
2 | 'temu | 2 |
3 | +/ | 25 |
4 | +0.16x10� | 1 |
5 | +17×10� | 1 |
6 | +²h� | 1 |
7 | +� | 2 |
8 | -0.01x10� | 1 |
9 | -0.56� | 1 |
10 | -0.69� | 1 |
11 | -0.91� | 1 |
12 | -226 | 2 |
13 | -2� | 1 |
14 | -983 | 1 |
15 | -actinin | 1 |
16 | -auc₀₋� | 2 |
17 | -catenins | 1 |
18 | -cf3ch� | 4 |
19 | -da1a | 2 |
20 | -dr� | 1 |
21 | -lactamases | 1 |
22 | -n� | 1 |
23 | -och� | 2 |
24 | -o� | 1 |
25 | -pi | 5 |
26 | -pka-nmda | 1 |
27 | -protocol | 1 |
28 | -relaxivities | 1 |
29 | -relaxivity | 3 |
30 | -subunit | 5 |
31 | -s₂ | 1 |
32 | -xkxbio₃ | 3 |
33 | -xtixo₃ | 2 |
34 | -x₄ | 1 |
35 | -y113a | 1 |
36 | -� | 1 |
37 | .ultrasound | 1 |
38 | .₅te₃ | 3 |
39 | //apps.who.int/trialsearch/trial.aspx | 4 |
40 | //apps.who.int/trialsearch/trial2.aspx | 1 |
41 | //clinicaltrials.gov/ct/show/nct00043758 | 1 |
42 | //clinicaltrials.gov/ct/show/nct00132743 | 1 |
43 | //clinicaltrials.gov/ct/show/nct00338260 | 3 |
44 | //clinicaltrials.gov/ct2/results | 2 |
45 | //clinicaltrials.gov/ct2/show/nct00088478 | 1 |
46 | //clinicaltrials.gov/ct2/show/nct00091962 | 2 |
47 | //clinicaltrials.gov/ct2/show/nct00206310 | 1 |
48 | //clinicaltrials.gov/ct2/show/nct00338962 | 1 |
49 | //clinicaltrials.gov/ct2/show/nct00472862 | 1 |
50 | //clinicaltrials.gov/ct2/show/nct00501579 | 1 |
51 | //clinicaltrials.gov/ct2/show/nct00562627 | 1 |
52 | //clinicaltrials.gov/ct2/show/nct00609778 | 1 |
53 | //clinicaltrials.gov/ct2/show/nct00611286 | 1 |
54 | //clinicaltrials.gov/ct2/show/nct00693849 | 1 |
55 | //clinicaltrials.gov/ct2/show/nct00789243 | 1 |
56 | //clinicaltrials.gov/ct2/show/nct00789828 | 1 |
57 | //clinicaltrials.gov/ct2/show/nct00849043 | 1 |
58 | //clinicaltrials.gov/ct2/show/nct00863798 | 1 |
59 | //clinicaltrials.gov/ct2/show/nct01141608 | 1 |
60 | //clinicaltrials.gov/ct2/show/nct01154023 | 1 |
61 | //clinicaltrials.gov/ct2/show/nct01178008 | 1 |
62 | //clinicaltrials.gov/ct2/show/nct01201837 | 1 |
63 | //clinicaltrials.gov/ct2/show/nct01294761 | 1 |
64 | //clinicaltrials.gov/ct2/show/nct01361932 | 1 |
65 | //clinicaltrials.gov/ct2/show/nct01384656 | 1 |
66 | //clinicaltrials.gov/ct2/show/nct01386853 | 1 |
67 | //clinicaltrials.gov/ct2/show/nct01398488 | 1 |
68 | //clinicaltrials.gov/ct2/show/nct01447966 | 1 |
69 | //clinicaltrials.gov/ct2/show/nct01556763 | 1 |
70 | //clinicaltrials.gov/ct2/show/nct01880710 | 1 |
71 | //clinicaltrials.gov/ct2/show/nct02016079 | 1 |
72 | //diagnosticpathology.slidepath.com/dih/webviewer.php | 2 |
73 | //drks-neu.uniklinik-freiburg.de/drks_web/navigate.do | 2 |
74 | //e-irb.khmccri.or.kr/eirb/receipt/index.html | 1 |
75 | //education.amjmed.com/video.php | 1 |
76 | //elearning.facs.org/mod/resource/view.php | 1 |
77 | //hvpmalaysia.kk.usm.my/mhgvc/index.php | 1 |
78 | //mht.mis.nchu.edu.tw/moodle/course/view.php | 1 |
79 | //public.ukcrn.org.uk/search/studydetail.aspx | 4 |
80 | //taylorandfrancis.metapress.com/openurl.asp | 2 |
81 | //upload.umin.ac.jp/cgi-open-bin/ctr/ctr.cgi | 3 |
82 | //www.anzctr.org.au/registry/trial_review.aspx | 2 |
83 | //www.anzctr.org.au/trial/registration/trialreview.aspx | 13 |
84 | //www.anzctr.org.au/trial_view.aspx | 14 |
85 | //www.cancer.gov/search/viewclinicaltrials.aspx | 1 |
86 | //www.cct.cuhk.edu.hk/registry/publictrialrecord.aspx | 1 |
87 | //www.chictr.org/cn/proj/show.aspx | 2 |
88 | //www.chictr.org/en/proj/show.aspx | 5 |
89 | //www.clinicaltrials.gov/ct/show/nct00114491 | 1 |
90 | //www.clinicaltrials.gov/ct/show/nct00174993 | 1 |
91 | //www.clinicaltrials.gov/ct/show/nct00344513 | 1 |
92 | //www.clinicaltrials.gov/ct2/results | 1 |
93 | //www.clinicaltrials.gov/ct2/show/nct00090324 | 1 |
94 | //www.clinicaltrials.gov/ct2/show/nct00106210 | 1 |
95 | //www.clinicaltrials.gov/ct2/show/nct00380731 | 1 |
96 | //www.clinicaltrials.gov/ct2/show/nct00449488 | 1 |
97 | //www.clinicaltrials.gov/ct2/show/nct00466193 | 1 |
98 | //www.clinicaltrials.gov/ct2/show/nct00540605 | 1 |
99 | //www.clinicaltrials.gov/ct2/show/nct00764868 | 1 |
100 | //www.clinicaltrials.gov/ct2/show/nct00772044 | 1 |
101 | //www.clinicaltrials.gov/ct2/show/nct00835003 | 1 |
102 | //www.clinicaltrials.gov/ct2/show/nct01952912 | 1 |
103 | //www.clinicaltrials.gov/ct2/show/nct02051426 | 1 |
104 | //www.controlled-trials.com/isrctn/search.html | 1 |
105 | //www.crd.york.ac.uk/prospero/display_record.asp | 1 |
106 | //www.hus.fi/ | 1 |
107 | //www.isrctn.com/isrctn39629189 | 1 |
108 | //www.moh.gov.sg/mohcorp/publications.aspx | 1 |
109 | //www.ncbi.nlm.nih.gov/geo/query/acc.cgi | 1 |
110 | //www.pactr.org/atmweb/appmanager/atm/atmregistry | 1 |
111 | //www.trialregister.nl/trialreg/admin/rctview.asp | 38 |
112 | /10� | 2 |
113 | /arginine | 1 |
114 | /c� | 1 |
115 | /il10� | 1 |
116 | /k� | 1 |
117 | /mt₂ | 1 |
118 | /t� | 1 |
119 | /μ | 1 |
120 | /₂ | 7 |
121 | /₃nb₂/₃ | 1 |
122 | /� | 2 |
123 | 0.06mmoll� | 1 |
124 | 0.0� | 1 |
125 | 0.41� | 1 |
126 | 0.4±185.7 | 1 |
127 | 0.51–0.62 | 1 |
128 | 0.5×10� | 1 |
129 | 0.6±1.8 | 1 |
130 | 0.8mmoll� | 1 |
131 | 0.92+0.38 | 1 |
132 | 0→� | 2 |
133 | 1-¹� | 1 |
134 | 1.0×10� | 2 |
135 | 1.10-5.28 | 1 |
136 | 1.2±0.5×10-3 | 1 |
137 | 1.2×10¹� | 1 |
138 | 1.3×10� | 1 |
139 | 1.8-m | 3 |
140 | 1.96×10� | 1 |
141 | 10-3 | 26 |
142 | 10.2×10� | 1 |
143 | 100g� | 2 |
144 | 100×10� | 1 |
145 | 10^� | 2 |
146 | 10¹² | 1 |
147 | 10¹¹ | 5 |
148 | 10¹� | 4 |
149 | 10� | 215 |
150 | 14-ring | 1 |
151 | 150×10� | 1 |
152 | 15q2 | 2 |
153 | 15·l·min� | 1 |
154 | 15� | 1 |
155 | 16-21� | 1 |
156 | 182.2/10� | 1 |
157 | 1d=450 | 1 |
158 | 1g/m2/h | 1 |
159 | 1×10� | 5 |
160 | 2.13×10� | 1 |
161 | 2.8±0.3mlmin₋� | 1 |
162 | 2.9±3.9 | 1 |
163 | 2.9×10� | 2 |
164 | 2000� | 1 |
165 | 20� | 1 |
166 | 23.5� | 1 |
167 | 25×10� | 1 |
168 | 27.8±12.4 | 1 |
169 | 274.9 | 2 |
170 | 2� | 5 |
171 | 3-o-linoleoyl-fb� | 1 |
172 | 3-o-oleoyl-fb� | 1 |
173 | 3-o-palmitoyl-fb� | 1 |
174 | 3.5×10� | 1 |
175 | 3.9±0.5mlmin₋� | 1 |
176 | 3.9×10¹� | 1 |
177 | 30-80×10� | 1 |
178 | 30×10� | 1 |
179 | 30� | 1 |
180 | 31.0� | 1 |
181 | 31.8� | 1 |
182 | 36� | 1 |
183 | 38� | 1 |
184 | 39� | 3 |
185 | 3p2 | 2 |
186 | 3x10� | 1 |
187 | 3×10� | 1 |
188 | 4.3134-0.0162 | 1 |
189 | 4.5g� | 1 |
190 | 4a� | 3 |
191 | 4b� | 2 |
192 | 4c� | 2 |
193 | 4x10� | 1 |
194 | 5-ht� | 6 |
195 | 5-o-linoleoyl-fb� | 1 |
196 | 5-o-oleoyl-fb� | 1 |
197 | 5-o-palmitoyl-fb� | 1 |
198 | 5.0×10� | 1 |
199 | 5.1×10� | 1 |
200 | 5.6×10¹� | 1 |
201 | 5.90×10� | 1 |
202 | 50-100×10� | 1 |
203 | 50×10� | 1 |
204 | 5×10� | 2 |
205 | 6.2� | 1 |
206 | 6.33×10� | 1 |
207 | 6.3640-0.0316 | 1 |
208 | 6.4� | 1 |
209 | 6.6� | 1 |
210 | 6.9� | 1 |
211 | 60.3±54.1 | 1 |
212 | 7,904 | 2 |
213 | 7.5� | 3 |
214 | 8.4×10� | 1 |
215 | 80×10� | 1 |
216 | 9.8×10� | 1 |
217 | 9� | 1 |
218 | :3.24±0.41 | 1 |
219 | :3.72±0.19 | 1 |
220 | =-.58 | 1 |
221 | =-.82 | 1 |
222 | =-.89 | 1 |
223 | =-0.143 | 1 |
224 | =-0.159 | 1 |
225 | =-0.182 | 1 |
226 | =-0.207 | 1 |
227 | =-0.217 | 1 |
228 | =-0.230 | 1 |
229 | =-0.295 | 1 |
230 | =-0.31 | 2 |
231 | =-0.32 | 4 |
232 | =-0.389 | 1 |
233 | =-0.43 | 2 |
234 | =-0.491 | 1 |
235 | =-0.61 | 1 |
236 | =-0.610 | 1 |
237 | =-0.65 | 1 |
238 | =-0.716 | 1 |
239 | =-0.740 | 1 |
240 | =-0.771 | 1 |
241 | =-0·73 | 1 |
242 | =-0·74 | 1 |
243 | =0.019 | 1 |
244 | =0.061 | 1 |
245 | =0.191 | 2 |
246 | =0.207 | 1 |
247 | =0.224 | 1 |
248 | =0.332 | 1 |
249 | =0.379 | 1 |
250 | =0.40-0.62 | 1 |
251 | =0.502 | 1 |
252 | =0.556 | 1 |
253 | =0.58-0.80 | 1 |
254 | =0.603 | 1 |
255 | =0.628 | 1 |
256 | =0.638 | 1 |
257 | =0.658 | 2 |
258 | =0.677 | 1 |
259 | =0.680 | 1 |
260 | =0.91-0.96 | 1 |
261 | =0·73 | 1 |
262 | =5.35 | 1 |
263 | =8660kg | 1 |
264 | _nfpb=true | 1 |
265 | `id | 1 |
266 | a-stimulated | 7 |
267 | a1� | 11 |
268 | abts•� | 1 |
269 | ab� | 1 |
270 | acc=gse38942 | 1 |
271 | acetaminophen� | 1 |
272 | acth� | 8 |
273 | action� | 1 |
274 | actrn=12609000885291 | 1 |
275 | actrn=12611000081910 | 1 |
276 | actrn=12611000929909 | 1 |
277 | actrn=12611000951954 | 1 |
278 | actrn=12612000132842 | 1 |
279 | acyw� | 1 |
280 | adh� | 12 |
281 | adrian | 1 |
282 | ads₃×s³×t� | 1 |
283 | afb� | 10 |
284 | afg� | 3 |
285 | aging.� | 1 |
286 | ag₃₂mpg� | 2 |
287 | ag₃₂sg� | 3 |
288 | ag� | 9 |
289 | ala³� | 1 |
290 | alcohol� | 1 |
291 | alk� | 1 |
292 | alpha2c-ar | 1 |
293 | alpha� | 7 |
294 | al³� | 11 |
295 | al₅₉ti₂₆cr� | 2 |
296 | al₆₆ti₂₄cr� | 2 |
297 | al� | 3 |
298 | am-treated | 3 |
299 | amico | 1 |
300 | ampli� | 3 |
301 | and2 | 3 |
302 | and� | 2 |
303 | antagonist/h� | 1 |
304 | anteiso-c� | 1 |
305 | anti-tnf- | 4 |
306 | anti� | 1 |
307 | aom/il10� | 1 |
308 | apj� | 1 |
309 | apob/lp-pla₂� | 4 |
310 | apoe� | 2 |
311 | appraisal� | 1 |
312 | arbs-at� | 1 |
313 | arg³� | 2 |
314 | arthritis� | 1 |
315 | arz� | 2 |
316 | asenapine-n� | 1 |
317 | asp²� | 1 |
318 | assessment� | 1 |
319 | ataxia� | 1 |
320 | atheism | 1 |
321 | attitudes� | 1 |
322 | at� | 22 |
323 | auc₀₋₄h | 2 |
324 | auc₀₋� | 10 |
325 | audadis� | 1 |
326 | au³� | 8 |
327 | au₃� | 2 |
328 | aw� | 1 |
329 | aβ₃� | 5 |
330 | aβ� | 3 |
331 | a₀ | 1 |
332 | a� | 37 |
333 | b-c� | 2 |
334 | b/angiotensin | 1 |
335 | background� | 1 |
336 | baclo₄� | 1 |
337 | ba²� | 2 |
338 | ba� | 3 |
339 | beats·min� | 6 |
340 | beat� | 1 |
341 | bene� | 4 |
342 | ben� | 1 |
343 | beta-lactams� | 1 |
344 | between� | 1 |
345 | be²� | 5 |
346 | bf₄� | 1 |
347 | bia� | 1 |
348 | bien | 5 |
349 | bifida� | 1 |
350 | bisul� | 1 |
351 | bi₀.₅sb� | 3 |
352 | bi₀.₉gd₀.� | 2 |
353 | bi₃.₆eu₀.₄ti₃o� | 1 |
354 | bi₅ti₃feo� | 3 |
355 | blicket | 1 |
356 | blt� | 1 |
357 | bolites | 1 |
358 | bound� | 1 |
359 | brain� | 1 |
360 | breaths·min� | 1 |
361 | brinolytic | 1 |
362 | broblasts | 1 |
363 | brosis | 1 |
364 | bw� | 2 |
365 | b� | 45 |
366 | c-n-r | 1 |
367 | c6� | 1 |
368 | cab� | 1 |
369 | cance | 4 |
370 | cant | 30 |
371 | cantly | 22 |
372 | car6� | 2 |
373 | carakasamhit� | 1 |
374 | cardean™ | 1 |
375 | cases/10� | 1 |
376 | catenatum+0.75×10� | 1 |
377 | ca²� | 150 |
378 | cb� | 17 |
379 | ccr7� | 1 |
380 | cd103� | 3 |
381 | cd11b� | 2 |
382 | cd11c� | 1 |
383 | cd133� | 2 |
384 | cd138� | 1 |
385 | cd14+cd16� | 1 |
386 | cd144� | 2 |
387 | cd14� | 16 |
388 | cd163� | 2 |
389 | cd16� | 4 |
390 | cd19� | 3 |
391 | cd1c� | 3 |
392 | cd24� | 2 |
393 | cd25� | 4 |
394 | cd27� | 3 |
395 | cd31� | 2 |
396 | cd34� | 1 |
397 | cd39� | 1 |
398 | cd3� | 17 |
399 | cd45ro� | 1 |
400 | cd4� | 129 |
401 | cd68� | 1 |
402 | cd85j� | 2 |
403 | cd8� | 41 |
404 | cdrid=68869 | 1 |
405 | cd²� | 2 |
406 | ce³� | 8 |
407 | ce₀.₇y₀.� | 1 |
408 | ce₂o₃d� | 1 |
409 | ce₂o₄� | 2 |
410 | ce₃o₅d₂� | 1 |
411 | ce₃o₆� | 2 |
412 | cf3cf� | 1 |
413 | ch-ch | 1 |
414 | ch2� | 6 |
415 | chcf3 | 2 |
416 | chcho | 4 |
417 | choh | 3 |
418 | choornam | 3 |
419 | chos� | 10 |
420 | chu� | 1 |
421 | ch� | 4 |
422 | ciency | 1 |
423 | cient | 3 |
424 | citabine | 1 |
425 | clairage | 1 |
426 | clo₄� | 2 |
427 | clstn3� | 1 |
428 | cl� | 4 |
429 | cmh2o� | 8 |
430 | cm� | 9 |
431 | code=02 | 1 |
432 | coenzymeq� | 1 |
433 | comet� | 1 |
434 | con� | 9 |
435 | coq� | 27 |
436 | costs'� | 1 |
437 | co²� | 7 |
438 | co³� | 1 |
439 | co₃²� | 1 |
440 | co� | 1 |
441 | cpα� | 1 |
442 | cross� | 1 |
443 | cr³� | 5 |
444 | cr₂o₇²� | 1 |
445 | cs� | 1 |
446 | ct2/show/nct00528515 | 1 |
447 | ct2/show/nct00931463 | 1 |
448 | ctla-4� | 4 |
449 | cum� | 4 |
450 | cu²� | 17 |
451 | cv� | 5 |
452 | cx₃cr1� | 4 |
453 | c¹� | 1 |
454 | c₂c� | 2 |
455 | c₂� | 5 |
456 | c₃� | 1 |
457 | c� | 23 |
458 | d'e� | 1 |
459 | d-cd1c� | 1 |
460 | d3-c� | 1 |
461 | databases� | 2 |
462 | days·week� | 2 |
463 | day� | 41 |
464 | dazzled | 1 |
465 | decade� | 4 |
466 | delta� | 2 |
467 | de� | 5 |
468 | df/emtri | 1 |
469 | dgemric-t� | 5 |
470 | dhy� | 1 |
471 | dh� | 1 |
472 | diet� | 2 |
473 | difference517 | 1 |
474 | difference551 | 1 |
475 | difference56 | 1 |
476 | disease.� | 1 |
477 | disorders� | 1 |
478 | dl� | 6 |
479 | doi=363175 | 1 |
480 | dopamine-d� | 2 |
481 | double� | 3 |
482 | dpph� | 1 |
483 | drug-na� | 3 |
484 | dr� | 2 |
485 | dsm� | 3 |
486 | dugdh� | 1 |
487 | dx� | 1 |
488 | dyn·s·cm� | 2 |
489 | dy³� | 2 |
490 | d·wk� | 2 |
491 | dødelige | 1 |
492 | dγ∕d� | 1 |
493 | d₂� | 2 |
494 | d₃� | 3 |
495 | d� | 50 |
496 | e/e� | 1 |
497 | ees=0.91 | 1 |
498 | efb� | 2 |
499 | ef� | 3 |
500 | ega-li� | 2 |
501 | emulsi� | 4 |
502 | enchondroma | 1 |
503 | endothelin-1� | 1 |
504 | ene | 3 |
505 | ep� | 3 |
506 | er³� | 15 |
507 | er� | 2 |
508 | esat� | 4 |
509 | esi� | 1 |
510 | et-1� | 8 |
511 | eucharist | 1 |
512 | eurekalert | 1 |
513 | eu³� | 9 |
514 | event_id=445 | 1 |
515 | events·h� | 1 |
516 | event� | 1 |
517 | ević | 1 |
518 | exercise� | 1 |
519 | experimenter� | 1 |
520 | ex� | 1 |
521 | e� | 16 |
522 | fa/ | 1 |
523 | factor-β� | 1 |
524 | factor-� | 1 |
525 | false� | 1 |
526 | family� | 1 |
527 | fast-food/burgers | 1 |
528 | fb� | 17 |
529 | fev� | 172 |
530 | fe²� | 12 |
531 | fe³� | 12 |
532 | fe� | 5 |
533 | fg� | 1 |
534 | fiury | 1 |
535 | follow� | 1 |
536 | forum/wikipathways-devel | 1 |
537 | forum/wikipathways-discuss | 1 |
538 | foxp3� | 4 |
539 | fuc� | 3 |
540 | function=brows | 3 |
541 | fú | 2 |
542 | f� | 36 |
543 | g/lb | 3 |
544 | ga� | 1 |
545 | gd³� | 2 |
546 | gender-speci� | 5 |
547 | genre=journal | 2 |
548 | gensh� | 1 |
549 | gfp� | 1 |
550 | glcnac₂-pa | 5 |
551 | glp1r� | 2 |
552 | glu¹� | 1 |
553 | glu� | 1 |
554 | glycolyl-u-¹� | 2 |
555 | gly³� | 1 |
556 | good/good/fair/poor | 1 |
557 | gpat1� | 6 |
558 | growed | 1 |
559 | gure-of-8-shaped | 1 |
560 | g·d� | 5 |
561 | g·kg� | 4 |
562 | g•kg� | 2 |
563 | g₀/g� | 5 |
564 | g� | 64 |
565 | haku | 1 |
566 | ham-d� | 14 |
567 | hamd� | 4 |
568 | hba� | 34 |
569 | hbt� | 3 |
570 | hco₃� | 18 |
571 | hemoglobin/g | 1 |
572 | her-2� | 1 |
573 | hg²� | 10 |
574 | hg� | 3 |
575 | hid� | 1 |
576 | high-mg²� | 2 |
577 | high� | 4 |
578 | his� | 1 |
579 | hit� | 3 |
580 | hiv� | 16 |
581 | hiy� | 1 |
582 | hko� | 4 |
583 | hla-b� | 1 |
584 | hoku | 2 |
585 | honzou | 1 |
586 | hours� | 1 |
587 | ho³� | 10 |
588 | hplc-esi� | 3 |
589 | hrsd� | 4 |
590 | hr� | 2 |
591 | hspg2� | 2 |
592 | hu� | 1 |
593 | h·d� | 2 |
594 | h·ng� | 4 |
595 | həli | 1 |
596 | h₂cit� | 1 |
597 | h₂₉n₃o₂ | 1 |
598 | h₃/h� | 4 |
599 | h₃o� | 2 |
600 | h₅/h� | 6 |
601 | h� | 101 |
602 | i4� | 1 |
603 | ibdv-speci� | 1 |
604 | id=25178 | 1 |
605 | id=308008 | 1 |
606 | id=308074 | 1 |
607 | id=335115 | 1 |
608 | id=335135 | 1 |
609 | id=335159 | 1 |
610 | id=335162 | 1 |
611 | id=335463 | 1 |
612 | id=335613 | 1 |
613 | id=335931 | 1 |
614 | id=336143 | 1 |
615 | id=343019 | 1 |
616 | id=343384 | 1 |
617 | id=347799 | 1 |
618 | id=347879 | 1 |
619 | id=362005 | 1 |
620 | id=362489 | 1 |
621 | id=362949 | 1 |
622 | id=7 | 1 |
623 | id=81688 | 1 |
624 | id=81803 | 1 |
625 | id=82159 | 1 |
626 | id=82509 | 1 |
627 | id=82878 | 1 |
628 | id=82978 | 1 |
629 | id=83071 | 1 |
630 | id=83667 | 1 |
631 | id=crd42011001468 | 1 |
632 | id=crd42013004364 | 1 |
633 | id=register | 1 |
634 | identified� | 1 |
635 | identi� | 8 |
636 | ifn� | 4 |
637 | igt� | 7 |
638 | ih� | 1 |
639 | ii° | 3 |
640 | il-4� | 1 |
641 | insufflation� | 1 |
642 | insulin-na� | 2 |
643 | interview� | 1 |
644 | intimacy� | 1 |
645 | in� | 1 |
646 | ip₃-ca²� | 1 |
647 | irbp� | 1 |
648 | ischemia-modi� | 1 |
649 | iso-c� | 1 |
650 | jak3� | 2 |
651 | ji� | 2 |
652 | jué | 1 |
653 | j� | 3 |
654 | kaku | 1 |
655 | kamp� | 1 |
656 | kcal·kg� | 1 |
657 | kcal•mol� | 2 |
658 | kermak | 1 |
659 | kg.m� | 1 |
660 | kg/1.7 | 1 |
661 | kg·m� | 2 |
662 | kg•m� | 1 |
663 | kg₋� | 2 |
664 | kg� | 303 |
665 | king� | 1 |
666 | kir2dl1/s1� | 1 |
667 | km·h� | 5 |
668 | know.� | 1 |
669 | komeri� | 1 |
670 | kom� | 1 |
671 | kulliyy� | 1 |
672 | ku� | 1 |
673 | kv·m� | 1 |
674 | k₂� | 1 |
675 | k� | 51 |
676 | l.min� | 1 |
677 | laboratory� | 1 |
678 | lacalut | 2 |
679 | lag-3� | 2 |
680 | large� | 1 |
681 | la₃ga₅sio� | 1 |
682 | la� | 8 |
683 | ldlr� | 4 |
684 | legibly | 1 |
685 | lessons� | 1 |
686 | life'� | 1 |
687 | lifestyle/mind | 1 |
688 | likelihood� | 1 |
689 | liter� | 4 |
690 | litre� | 3 |
691 | li� | 1 |
692 | ln³� | 4 |
693 | log₋� | 2 |
694 | log� | 28 |
695 | los100� | 3 |
696 | los150� | 4 |
697 | losartan-at� | 1 |
698 | low� | 5 |
699 | lozano | 1 |
700 | ltration | 1 |
701 | lt� | 4 |
702 | lu/10� | 1 |
703 | lvarez | 1 |
704 | lys²� | 4 |
705 | lys³� | 1 |
706 | l·min� | 12 |
707 | l₅-s� | 1 |
708 | l� | 110 |
709 | m-b� | 4 |
710 | m-units·m� | 3 |
711 | mag� | 1 |
712 | mahg� | 2 |
713 | malaky� | 1 |
714 | man₂xyl� | 1 |
715 | man₃xyl� | 2 |
716 | man� | 2 |
717 | maq� | 1 |
718 | mass� | 3 |
719 | max� | 3 |
720 | mbq� | 2 |
721 | mc� | 1 |
722 | medizinischen | 9 |
723 | menc-crm� | 5 |
724 | meq·l� | 4 |
725 | methyl-¹� | 1 |
726 | methylation-speci� | 1 |
727 | met¹²� | 1 |
728 | met¹� | 1 |
729 | mg.kg� | 9 |
730 | mgkg� | 1 |
731 | mg²� | 32 |
732 | mg·dl� | 4 |
733 | mg·d� | 4 |
734 | mg·g� | 6 |
735 | mg·kg� | 16 |
736 | mg·l� | 6 |
737 | mg·ml� | 1 |
738 | mg·steer� | 1 |
739 | mg×kg� | 2 |
740 | mg•kg� | 1 |
741 | mg∙kg� | 6 |
742 | mg� | 32 |
743 | micromol·l� | 1 |
744 | mikimiki | 3 |
745 | mins.wk� | 1 |
746 | minute� | 1 |
747 | min·session� | 1 |
748 | min₋� | 7 |
749 | min� | 105 |
750 | mirtazapine–first� | 1 |
751 | mirtazapine� | 1 |
752 | mitogen� | 1 |
753 | mi� | 1 |
754 | mj� | 1 |
755 | ml.kg� | 2 |
756 | ml.min� | 1 |
757 | ml·kg� | 23 |
758 | ml·min� | 4 |
759 | ml·yr� | 1 |
760 | ml� | 133 |
761 | mmhg₋� | 6 |
762 | mmol.l� | 1 |
763 | mmol·kg� | 1 |
764 | mmol·l� | 7 |
765 | mmol·min·l� | 1 |
766 | mmp� | 1 |
767 | mm� | 2 |
768 | mnbr₄²� | 1 |
769 | mncl₄²� | 1 |
770 | mnx₄²� | 1 |
771 | mn²� | 6 |
772 | model� | 1 |
773 | modi� | 1 |
774 | molecule� | 2 |
775 | mol� | 9 |
776 | monoene | 1 |
777 | monoenyl | 1 |
778 | month� | 1 |
779 | morphology� | 1 |
780 | mosm.kg� | 1 |
781 | mosmol·kg� | 1 |
782 | mosm·kg� | 1 |
783 | mp2x� | 2 |
784 | mpowered | 1 |
785 | mpp� | 2 |
786 | ms� | 1 |
787 | mt� | 2 |
788 | mujer | 4 |
789 | mutants/10� | 1 |
790 | mu·min·l� | 1 |
791 | mu·m� | 2 |
792 | mu� | 1 |
793 | m·s� | 3 |
794 | m� | 158 |
795 | n-acyl-fb� | 2 |
796 | n-c₆h� | 2 |
797 | n-linoleoyl-fb� | 1 |
798 | n-oleoyl-fb� | 1 |
799 | n-palmitoyl-fb� | 3 |
800 | nad� | 29 |
801 | nakanda | 1 |
802 | nau/whakapapa | 1 |
803 | navigationid=trial.html | 2 |
804 | nazn� | 2 |
805 | na� | 39 |
806 | nct00376571 | 1 |
807 | nct00643760 | 1 |
808 | nc� | 1 |
809 | ndex | 1 |
810 | ndice | 1 |
811 | nd³� | 13 |
812 | ng·ml� | 3 |
813 | ng� | 2 |
814 | nhxyn11� | 4 |
815 | nh₃/nh₄� | 2 |
816 | nh₄� | 2 |
817 | nh� | 4 |
818 | nicu-bazr₀.� | 1 |
819 | nilavembu | 4 |
820 | nization | 2 |
821 | ni²� | 4 |
822 | nk� | 6 |
823 | non-m� | 22 |
824 | non� | 1 |
825 | no₂� | 15 |
826 | no₃� | 11 |
827 | ntf₂� | 1 |
828 | n·kg� | 1 |
829 | n·s� | 4 |
830 | nī | 2 |
831 | n₂� | 1 |
832 | n� | 16 |
833 | o-acyl-fb� | 1 |
834 | o-b | 3 |
835 | o-b� | 3 |
836 | observer� | 1 |
837 | oh� | 1 |
838 | onoo� | 2 |
839 | on� | 1 |
840 | open� | 1 |
841 | order=1 | 4 |
842 | order=1cp | 1 |
843 | order_1 | 1 |
844 | ori | 142 |
845 | ori/non-pacific | 1 |
846 | otf� | 1 |
847 | outcasts | 1 |
848 | outcomes� | 2 |
849 | oxycodone� | 7 |
850 | o₂·kg� | 2 |
851 | o₂·� | 5 |
852 | o₂•� | 1 |
853 | o₂� | 7 |
854 | o₃₉ | 4 |
855 | o₃₋δ | 1 |
856 | o� | 11 |
857 | p,0 | 1 |
858 | p.met1 | 1 |
859 | p23� | 3 |
860 | p2y� | 13 |
861 | p2� | 14 |
862 | p53� | 3 |
863 | p=1.1´10� | 1 |
864 | p=1.3×10� | 1 |
865 | p=2.9´10� | 1 |
866 | p=5.2´10� | 1 |
867 | p=6.9´10� | 1 |
868 | participant-witnesses | 1 |
869 | path=1 | 1 |
870 | patients� | 1 |
871 | pc₇� | 2 |
872 | pd-1� | 5 |
873 | pdapp� | 7 |
874 | pd� | 1 |
875 | people-m� | 1 |
876 | pf₆� | 1 |
877 | pga� | 7 |
878 | pg� | 2 |
879 | phase� | 1 |
880 | phenyl-u-¹� | 2 |
881 | phn� | 1 |
882 | placebo� | 1 |
883 | pmol·kg� | 6 |
884 | pmol·l� | 4 |
885 | pmol� | 4 |
886 | pm� | 9 |
887 | population� | 1 |
888 | posadzki | 1 |
889 | possible.� | 1 |
890 | post� | 11 |
891 | prede� | 1 |
892 | preschool-si | 1 |
893 | prespeci� | 1 |
894 | proj=1618 | 1 |
895 | proj=2132 | 1 |
896 | proj=2384 | 1 |
897 | proj=2561 | 1 |
898 | proj=3486 | 1 |
899 | proj=3820 | 1 |
900 | proj=3904 | 1 |
901 | protein� | 2 |
902 | protezama | 1 |
903 | pro� | 2 |
904 | pr³� | 2 |
905 | ps19� | 3 |
906 | pt� | 4 |
907 | pvp-ag� | 1 |
908 | py3 | 1 |
909 | p� | 9 |
910 | q=39629189 | 1 |
911 | qaw� | 1 |
912 | qids-sr� | 2 |
913 | qìg� | 1 |
914 | q� | 19 |
915 | r-blocking | 1 |
916 | r-ch� | 5 |
917 | r1� | 2 |
918 | rac·steer� | 4 |
919 | range� | 1 |
920 | rb� | 4 |
921 | re-nhxyn11� | 3 |
922 | re=v*d*� | 1 |
923 | recognition� | 1 |
924 | refused� | 1 |
925 | regularly� | 1 |
926 | rehabilitationsverfahren | 1 |
927 | reps·min� | 2 |
928 | reviews� | 1 |
929 | re³� | 2 |
930 | rf� | 3 |
931 | rg� | 3 |
932 | rh� | 1 |
933 | risk� | 1 |
934 | rjuna | 1 |
935 | rmed | 2 |
936 | rnica | 9 |
937 | rorγt� | 5 |
938 | ros1� | 1 |
939 | ruih� | 1 |
940 | rydberg� | 1 |
941 | ryū | 1 |
942 | ry� | 1 |
943 | rδ� | 5 |
944 | r� | 12 |
945 | s/cm� | 1 |
946 | s1� | 1 |
947 | saffron.� | 1 |
948 | saludable | 2 |
949 | sam� | 1 |
950 | sankhy� | 2 |
951 | sasa | 16 |
952 | sb-c� | 1 |
953 | sca� | 14 |
954 | schedule� | 1 |
955 | scienti� | 2 |
956 | sec� | 3 |
957 | seis� | 1 |
958 | self� | 4 |
959 | ser¹¹� | 1 |
960 | ser� | 8 |
961 | seven� | 1 |
962 | sex� | 4 |
963 | sfcs/10� | 1 |
964 | shu� | 1 |
965 | shí | 2 |
966 | sh� | 4 |
967 | signi� | 40 |
968 | single-object | 1 |
969 | single� | 1 |
970 | slr� | 1 |
971 | sl� | 1 |
972 | snapshotid=13617947952577 | 1 |
973 | snapshotid=13617948230017 | 1 |
974 | sn� | 1 |
975 | solid� | 1 |
976 | sorry | 6 |
977 | sp/nk� | 2 |
978 | spreaded | 1 |
979 | srch=isrctn84130388 | 1 |
980 | src� | 13 |
981 | sst� | 1 |
982 | standard� | 1 |
983 | star� | 4 |
984 | sta� | 1 |
985 | steer� | 1 |
986 | sterolq� | 4 |
987 | stretch� | 2 |
988 | studyid=10479 | 1 |
989 | studyid=13538 | 1 |
990 | studyid=4058 | 1 |
991 | studyid=7285 | 1 |
992 | stufenverfahren | 1 |
993 | sub-g� | 1 |
994 | sure.� | 1 |
995 | suvmax� | 1 |
996 | symptoms� | 2 |
997 | syndrome� | 1 |
998 | s� | 35 |
999 | t1� | 9 |
1000 | tae-j� | 1 |
1001 | take10 | 2 |
1002 | tau50 | 3 |
1003 | tb³� | 1 |
1004 | tb� | 4 |
1005 | tc=1123 | 1 |
1006 | tc=1155 | 1 |
1007 | tc=1351 | 1 |
1008 | tc=1576 | 1 |
1009 | tc=1639 | 1 |
1010 | tc=1696 | 1 |
1011 | tc=1786 | 1 |
1012 | tc=1836 | 1 |
1013 | tc=1867 | 1 |
1014 | tc=1892 | 1 |
1015 | tc=2018 | 1 |
1016 | tc=2058 | 1 |
1017 | tc=2126 | 1 |
1018 | tc=2168 | 2 |
1019 | tc=2233 | 1 |
1020 | tc=2297 | 2 |
1021 | tc=2303 | 1 |
1022 | tc=2584 | 1 |
1023 | tc=2665 | 1 |
1024 | tc=2922 | 1 |
1025 | tc=2993 | 1 |
1026 | tc=3007 | 1 |
1027 | tc=3045 | 1 |
1028 | tc=3102 | 1 |
1029 | tc=3116 | 2 |
1030 | tc=3147 | 1 |
1031 | tc=3288 | 1 |
1032 | tc=3377 | 1 |
1033 | tc=3396 | 1 |
1034 | tc=3596 | 1 |
1035 | tc=4169 | 1 |
1036 | tc=467 | 1 |
1037 | tc=703 | 1 |
1038 | tc=820 | 1 |
1039 | tc=854 | 1 |
1040 | temperature.� | 1 |
1041 | term=00863798 | 1 |
1042 | term=behavioral+intervention+for+insomnia+in+older+adults | 1 |
1043 | term=cer-001 | 1 |
1044 | term=corona | 1 |
1045 | term=desipramine+and+alcohol+dependence+and+depression | 1 |
1046 | term=exist-1 | 1 |
1047 | term=gik+and+opcab | 1 |
1048 | term=gottlieb+tablet+pc+education | 1 |
1049 | term=hysterectomy | 1 |
1050 | term=international+study+to+predict+optimized+treatment+for+depression | 1 |
1051 | term=linc | 1 |
1052 | term=mauritius | 1 |
1053 | term=mtn-002 | 1 |
1054 | term=nct00371176 | 1 |
1055 | term=nct00789243 | 1 |
1056 | term=nct00835003 | 1 |
1057 | term=nct01157416 | 1 |
1058 | term=nct01157429 | 1 |
1059 | term=nct01361932 | 1 |
1060 | term=nct01386853 | 1 |
1061 | term=nct01556763 | 1 |
1062 | term=nct016301952912 | 1 |
1063 | term=nct02051426 | 1 |
1064 | term=neurocom | 1 |
1065 | term=ocd+and+st+petersburg | 1 |
1066 | term=olanzapine+depot | 1 |
1067 | term=opal-hiv-1001 | 1 |
1068 | term=postpartum+acupuncture | 1 |
1069 | term=prodigy | 1 |
1070 | term=quetiapine+112 | 1 |
1071 | term=rollman+cabg | 2 |
1072 | term=sirion | 1 |
1073 | term=social+anxiety+cognitive+behavioral+therapy+stanford | 1 |
1074 | term=spare | 1 |
1075 | term=spd489-306 | 1 |
1076 | term=spreng | 1 |
1077 | term=stimulant+reduction+intervention+using+dosed+exercise | 1 |
1078 | term=ventus | 1 |
1079 | term=ventus+medical | 1 |
1080 | term=voors | 1 |
1081 | tgenr-nad� | 2 |
1082 | tgf-β� | 8 |
1083 | tgfβ� | 3 |
1084 | tgf� | 1 |
1085 | three� | 1 |
1086 | thr³� | 2 |
1087 | tie2� | 2 |
1088 | tim-3� | 3 |
1089 | time� | 3 |
1090 | tissue� | 1 |
1091 | ti� | 2 |
1092 | tk� | 1 |
1093 | tm³� | 5 |
1094 | tnf-� | 2 |
1095 | trans-cf3ch� | 2 |
1096 | trans-chcl� | 2 |
1097 | transform-us | 5 |
1098 | treatment-na� | 2 |
1099 | trialid=actrn12610000257066 | 1 |
1100 | trialid=actrn12610000958088 | 1 |
1101 | trialid=actrn12611001256965 | 1 |
1102 | trialid=cuhk_cct00037 | 1 |
1103 | trialid=drks00003322 | 1 |
1104 | trialid=ntr1862 | 1 |
1105 | trienyl | 2 |
1106 | two� | 1 |
1107 | t₂₂� | 1 |
1108 | t₄/t� | 2 |
1109 | t₅-t� | 1 |
1110 | t₈� | 2 |
1111 | t₉-l� | 1 |
1112 | t� | 82 |
1113 | u-¹� | 1 |
1114 | ugml� | 1 |
1115 | uncombinable | 1 |
1116 | use.� | 1 |
1117 | u·mg� | 1 |
1118 | u� | 3 |
1119 | v.cm� | 1 |
1120 | vanc� | 8 |
1121 | vef� | 1 |
1122 | vegf� | 6 |
1123 | ventilator� | 1 |
1124 | vi-crm� | 7 |
1125 | vldl� | 13 |
1126 | vol� | 2 |
1127 | v� | 8 |
1128 | week� | 9 |
1129 | weight� | 1 |
1130 | whether/how | 1 |
1131 | whom.� | 1 |
1132 | wh� | 1 |
1133 | wild� | 1 |
1134 | wissenschaftlicher | 1 |
1135 | wmfev� | 3 |
1136 | wm� | 3 |
1137 | wt� | 3 |
1138 | www.anzctr.org.au/trial_view.aspx | 1 |
1139 | www.clinicaltrials.gov/ct/show/nct00194454 | 1 |
1140 | www.clinicaltrials.gov/ct2/results | 1 |
1141 | www.crd.york.ac.uk/prospero/display_record.asp | 1 |
1142 | www.karger.com/ | 1 |
1143 | www.trialregister.nl/trialreg/admin/rctview.asp | 2 |
1144 | w·min� | 1 |
1145 | w·m� | 6 |
1146 | w� | 7 |
1147 | xed | 2 |
1148 | xi� | 2 |
1149 | xyl� | 2 |
1150 | x³b� | 1 |
1151 | x³σg� | 3 |
1152 | xī | 1 |
1153 | x̃ | 12 |
1154 | x� | 2 |
1155 | y=5.873×10� | 1 |
1156 | yana-s | 1 |
1157 | yat | 1 |
1158 | yb³� | 28 |
1159 | yb₀.� | 1 |
1160 | year� | 4 |
1161 | y³� | 1 |
1162 | y₃ga₅o� | 2 |
1163 | y� | 1 |
1164 | z-ho-ch� | 3 |
1165 | zebra� | 1 |
1166 | zhèngz� | 1 |
1167 | zh� | 3 |
1168 | zjaz | 3 |
1169 | zn²� | 12 |
1170 | z� | 3 |
1171 | |midi | 1 |
1172 | |� | 2 |
1173 | � | 1 |
1174 | ¡cuídate | 2 |
1175 | ²-p2� | 1 |
1176 | ²h-³¹p₃� | 1 |
1177 | ²h-³¹p� | 1 |
1178 | ²h� | 1 |
1179 | ²³� | 6 |
1180 | ²� | 22 |
1181 | ³� | 10 |
1182 | µg·ml� | 1 |
1183 | µm/10� | 1 |
1184 | µmol·l� | 1 |
1185 | µv� | 2 |
1186 | ·min� | 1 |
1187 | ·pro·� | 1 |
1188 | ¹²� | 13 |
1189 | ¹³c� | 9 |
1190 | ¹³� | 38 |
1191 | ¹� | 83 |
1192 | ×10-3 | 1 |
1193 | ×10� | 11 |
1194 | ×min� | 1 |
1195 | †| 1 |
1196 | å³.°c� | 1 |
1197 | ín | 1 |
1198 | ódź | 8 |
1199 | α-pw� | 4 |
1200 | α₄β₇� | 2 |
1201 | α� | 17 |
1202 | β-amyloid� | 1 |
1203 | β-k₂bi₈se� | 3 |
1204 | β₂γ | 1 |
1205 | β� | 26 |
1206 | γ₂ | 5 |
1207 | γ� | 2 |
1208 | δa₅� | 2 |
1209 | δfev� | 3 |
1210 | δpost-fev� | 4 |
1211 | δpre-fev� | 4 |
1212 | δ¹� | 12 |
1213 | δ� | 28 |
1214 | η� | 2 |
1215 | θd� | 1 |
1216 | κoλλυ� | 1 |
1217 | κ� | 1 |
1218 | μg.kg� | 2 |
1219 | μg·kg� | 3 |
1220 | μg·l� | 1 |
1221 | μg×kg� | 1 |
1222 | μg� | 2 |
1223 | μl/well | 3 |
1224 | μmol·g� | 1 |
1225 | μmol·kg� | 2 |
1226 | μmol·min� | 1 |
1227 | μmol∙h∙l� | 1 |
1228 | μvk� | 2 |
1229 | ν� | 3 |
1230 | π� | 1 |
1231 | σ� | 6 |
1232 | χ²� | 5 |
1233 | ω� | 1 |
1234 | ер2 | 2 |
1235 | о₂greater | 1 |
1236 | рм� | 1 |
1237 | с� | 1 |
1238 | ṣid | 1 |
1239 | “aces� | 1 |
1240 | “aminals� | 1 |
1241 | “at-risk� | 3 |
1242 | “cracking� | 1 |
1243 | “disorganization� | 1 |
1244 | “early� | 1 |
1245 | “efficiency� | 1 |
1246 | “exercise� | 1 |
1247 | “experience� | 1 |
1248 | “fair� | 1 |
1249 | “fingerprinting� | 1 |
1250 | “good� | 6 |
1251 | “high� | 1 |
1252 | “hospice� | 1 |
1253 | “in-motion� | 2 |
1254 | “infection | 1 |
1255 | “luxury.� | 1 |
1256 | “myelomeningocele | 1 |
1257 | “normalization� | 1 |
1258 | “opioid� | 1 |
1259 | “out-of-proportion� | 3 |
1260 | “palliative� | 1 |
1261 | “patient-specific� | 1 |
1262 | “pleasant.� | 1 |
1263 | “pleasant� | 1 |
1264 | “preactivated� | 1 |
1265 | “program� | 1 |
1266 | “proper� | 1 |
1267 | “real-world� | 1 |
1268 | “regular� | 1 |
1269 | “soft-option� | 1 |
1270 | “sport� | 1 |
1271 | “stable� | 1 |
1272 | “statins� | 1 |
1273 | “thin� | 1 |
1274 | “training� | 1 |
1275 | “unclear� | 1 |
1276 | “unclosed� | 1 |
1277 | “unpleasant� | 1 |
1278 | ₀ | 116 |
1279 | ₀/d | 1 |
1280 | ₀/grams | 1 |
1281 | ₀copies/ml | 1 |
1282 | ₀iu/ml | 1 |
1283 | ₀₀ | 6 |
1284 | ₀₀c | 1 |
1285 | ₀₄₋₃₆₃ | 8 |
1286 | ₀₆₋₃₂₄ | 4 |
1287 | ₀₋� | 1 |
1288 | ₂ | 163 |
1289 | ₂-adp | 1 |
1290 | ₂-dependent | 1 |
1291 | ₂h� | 1 |
1292 | ₂₀ | 4 |
1293 | ₂� | 4 |
1294 | ₃- | 1 |
1295 | ₃-type | 1 |
1296 | ₃.₈ | 4 |
1297 | ₃co₄ | 3 |
1298 | ₃f | 1 |
1299 | ₃²� | 1 |
1300 | ₃³� | 2 |
1301 | ₃� | 2 |
1302 | ₄and | 1 |
1303 | ₄n� | 3 |
1304 | ₄₂ | 1 |
1305 | ₄� | 1 |
1306 | ₅ | 18 |
1307 | ₅=18.33 | 1 |
1308 | ₅min | 2 |
1309 | ₆ | 24 |
1310 | ₆-c₂₂ | 1 |
1311 | ₆-labeled | 1 |
1312 | ₆h₉o7 | 1 |
1313 | ₆₅b | 6 |
1314 | ₆₈ | 1 |
1315 | ₇ | 26 |
1316 | ₇fe₅₂ge� | 4 |
1317 | ₈ | 5 |
1318 | ₈-column | 1 |
1319 | ₈.₂ | 1 |
1320 | ₈h₂o | 1 |
1321 | ₈h₂₉o₂· | 1 |
1322 | ₈₀ | 2 |
1323 | ₉ | 7 |
1324 | ₉-c₂₃ | 1 |
1325 | ₉₂ | 2 |
1326 | ₉₂-sta� | 3 |
1327 | ₉₂g | 1 |
1328 | ₉₇ | 14 |
1329 | ₉� | 1 |
1330 | ₋₂₀ | 1 |
1331 | ₋₂₄ | 6 |
1332 | ₋₂₄-stimulated | 2 |
1333 | ₋₃ | 1 |
1334 | ₋₃/dp | 1 |
1335 | ₋₃₅ | 3 |
1336 | ₋₃₅-induced | 2 |
1337 | ₋₃₆₃ | 2 |
1338 | ₋₃� | 9 |
1339 | ₋₄ | 2 |
1340 | ₋₄-subunits | 1 |
1341 | ₋₄₀ | 1 |
1342 | ₋₄₂ | 3 |
1343 | ₋� | 5 |
1344 | →0 | 1 |
1345 | →cc | 1 |
1346 | →²f₇/₂ | 1 |
1347 | ⇒� | 1 |
1348 | ∇� | 1 |
1349 | ∠o� | 1 |
1350 | ∼10� | 1 |
1351 | ∼c� | 1 |
1352 | ≈10� | 1 |
1353 | ≤1.3×10� | 1 |
1354 | ≤125×10� | 1 |
1355 | ≥.56 | 1 |
1356 | ≥10¹� | 2 |
1357 | ≥10� | 1 |
1358 | △� | 2 |
1359 | 大黃附� | 1 |
1360 | 妇� | 1 |
1361 | 平� | 1 |
1362 | 春胶囊 | 1 |
1363 | 湯 | 1 |
1364 | 潜阳 | 1 |
1365 | 瘀胶囊 | 1 |
1366 | 血府� | 1 |
1367 | � | 2,038 |
1368 | �+mg²� | 2 |
1369 | �- | 1 |
1370 | �-17� | 1 |
1371 | �-2-methyl-oxodienyl | 2 |
1372 | �-3-keto | 2 |
1373 | �-33� | 1 |
1374 | �-39� | 1 |
1375 | �-activated | 3 |
1376 | �-ala³� | 2 |
1377 | �-alkylguanine | 1 |
1378 | �-aminopropylspermine | 1 |
1379 | �-atpase | 13 |
1380 | �-benzyladenine-type | 1 |
1381 | �-binding | 3 |
1382 | �-codoped | 4 |
1383 | �-conducting | 1 |
1384 | �-cp₃o₆ | 1 |
1385 | �-dependent | 3 |
1386 | �-depleted | 1 |
1387 | �-doped | 2 |
1388 | �-encoding | 1 |
1389 | �-evoked | 4 |
1390 | �-glucuronide | 1 |
1391 | �-gly³� | 1 |
1392 | �-hrms/ms | 3 |
1393 | �-iminodiacetic | 1 |
1394 | �-independent | 2 |
1395 | �-induced | 6 |
1396 | �-influx | 1 |
1397 | �-ions | 1 |
1398 | �-k� | 6 |
1399 | �-linked | 1 |
1400 | �-mg | 3 |
1401 | �-mg²� | 2 |
1402 | �-modes | 1 |
1403 | �-ms/ms | 1 |
1404 | �-ocn | 2 |
1405 | �-osteocalcin | 1 |
1406 | �-permeable | 1 |
1407 | �-related | 1 |
1408 | �-secreting | 2 |
1409 | �-sensor | 1 |
1410 | �-ser³� | 1 |
1411 | �-tb³� | 1 |
1412 | �-tetrahydrocannabinol | 10 |
1413 | �-tetrahydrocannabinol/thc | 1 |
1414 | �-thc | 16 |
1415 | �-thc-induced | 1 |
1416 | �-triggered | 1 |
1417 | �-urea | 1 |
1418 | �-wo₃ | 1 |
1419 | �-yb³� | 3 |
1420 | �.� | 1 |
1421 | �/41� | 2 |
1422 | �/a� | 4 |
1423 | �/c-kit� | 1 |
1424 | �/calmodulin-kinase | 1 |
1425 | �/ca²� | 1 |
1426 | �/cd16� | 1 |
1427 | �/cd1a� | 1 |
1428 | �/cd34� | 2 |
1429 | �/cd3� | 1 |
1430 | �/cd8� | 6 |
1431 | �/d-glucose | 1 |
1432 | �/er³� | 4 |
1433 | �/fe²� | 1 |
1434 | �/hcit²� | 1 |
1435 | �/ho³� | 1 |
1436 | �/h₃o� | 1 |
1437 | �/kir2dl2/l3/s2� | 1 |
1438 | �/k� | 5 |
1439 | �/l | 47 |
1440 | �/l-5.8 | 1 |
1441 | �/mc� | 4 |
1442 | �/ml | 3 |
1443 | �/mnx₄²� | 1 |
1444 | �/m² | 1 |
1445 | �/nadh | 3 |
1446 | �/nkg2d� | 2 |
1447 | �/s | 2 |
1448 | �/sca1� | 1 |
1449 | �/taurocholate | 1 |
1450 | �/tio₂ | 1 |
1451 | �/tm³� | 1 |
1452 | �/u� | 2 |
1453 | �/vegfr2� | 2 |
1454 | �/yb³� | 2 |
1455 | �/� | 2 |
1456 | �/μl | 4 |
1457 | �/� | 40 |
1458 | �10 | 1 |
1459 | �15 | 1 |
1460 | �20 | 1 |
1461 | �2001 | 1 |
1462 | �30 | 1 |
1463 | �5 | 1 |
1464 | �5201 | 1 |
1465 | �=0.05 | 1 |
1466 | �al | 6 |
1467 | �atpase | 1 |
1468 | �be | 2 |
1469 | �c | 34 |
1470 | �c-labeled | 2 |
1471 | �c-urea | 1 |
1472 | �ca | 4 |
1473 | �cd127 | 1 |
1474 | �cd16� | 5 |
1475 | �cd24� | 1 |
1476 | �cd25 | 5 |
1477 | �cd25� | 5 |
1478 | �cd4� | 2 |
1479 | �cd56� | 6 |
1480 | �cd8� | 2 |
1481 | �cfu | 1 |
1482 | �cfu/animal/day | 1 |
1483 | �cm2 | 1 |
1484 | �codeine | 1 |
1485 | �co₂ | 2 |
1486 | �cr | 7 |
1487 | �cs | 38 |
1488 | �cu-labeled | 1 |
1489 | �cu-raft-rgd | 6 |
1490 | �d | 2 |
1491 | �d-child | 1 |
1492 | �day | 5 |
1493 | �dha | 1 |
1494 | �d₀ | 1 |
1495 | �elders | 1 |
1496 | �f | 11 |
1497 | �f-fdg | 2 |
1498 | �f-fluoride | 2 |
1499 | �f-fluoro-2-deoxy-d-glucose | 1 |
1500 | �f-fluorodeoxy-glucose | 1 |
1501 | �f-fluorodeoxyglucose | 3 |
1502 | �f-fluorodeoxyglucose-pet | 1 |
1503 | �f-fluorodeoxyglucose-positron | 1 |
1504 | �f-galacto-rgd | 1 |
1505 | �f-nifene | 1 |
1506 | �f-nifrolene | 7 |
1507 | �f-nifrolidine | 2 |
1508 | �f-nifzetidine | 2 |
1509 | �f-nmr | 1 |
1510 | �f-pet | 4 |
1511 | �f9/2 | 1 |
1512 | �fdg | 1 |
1513 | �fdg-pet | 1 |
1514 | �fe | 5 |
1515 | �fluoro-deoxyglucose | 1 |
1516 | �foxp3� | 4 |
1517 | �f₄ | 1 |
1518 | �g/g | 1 |
1519 | �g/ml | 1 |
1520 | �ga | 16 |
1521 | �ga-labeled | 3 |
1522 | �ga-labeling | 2 |
1523 | �ga-nodaga-c | 1 |
1524 | �ga-radiopharmaceuticals | 1 |
1525 | �ga-trap | 3 |
1526 | �gender | 4 |
1527 | �gln | 4 |
1528 | �gr-1� | 1 |
1529 | �h | 2 |
1530 | �hctz | 5 |
1531 | �hctz25 | 3 |
1532 | �hctz37.5 | 4 |
1533 | �homeostasis | 1 |
1534 | �i | 10 |
1535 | �i-echistatin | 1 |
1536 | �i-f-hbsag | 1 |
1537 | �i-h-hbsag | 1 |
1538 | �i-radiolabeled | 1 |
1539 | �i-ttr | 1 |
1540 | �i15/2 | 1 |
1541 | �iams | 2 |
1542 | �itching | 1 |
1543 | �i₈ | 1 |
1544 | �k | 3 |
1545 | �kg | 4 |
1546 | �kg� | 1 |
1547 | �l� | 8 |
1548 | �m | 1 |
1549 | �management | 1 |
1550 | �mdc-ra | 1 |
1551 | �mg | 2 |
1552 | �min | 4 |
1553 | �ml | 4 |
1554 | �mnps | 1 |
1555 | �mobilization | 1 |
1556 | �mtc | 5 |
1557 | �mtc-lp-cooh | 2 |
1558 | �mtc-sestamibi | 1 |
1559 | �n | 18 |
1560 | �n-enrichment | 1 |
1561 | �na | 1 |
1562 | �nanimal | 2 |
1563 | �ndiet | 2 |
1564 | �no | 2 |
1565 | �n₂ | 1 |
1566 | �or | 2 |
1567 | �p*l | 1 |
1568 | �point | 1 |
1569 | �reviewed� | 1 |
1570 | �s | 17 |
1571 | �s3/2 | 1 |
1572 | �salmeterol | 2 |
1573 | �selected | 1 |
1574 | �si | 5 |
1575 | �si-nmr | 2 |
1576 | �span | 2 |
1577 | �s₂ | 1 |
1578 | �t | 1 |
1579 | �t-cell | 1 |
1580 | �t/cd8� | 1 |
1581 | �tc-extametazime-labeled | 1 |
1582 | �total | 1 |
1583 | �t₂ | 1 |
1584 | �t� | 1 |
1585 | �u | 6 |
1586 | �week | 1 |
1587 | �x+17075.659 | 1 |
1588 | �² | 68 |
1589 | �²-12.2×10� | 1 |
1590 | �²-9.7×10� | 1 |
1591 | �²ca | 1 |
1592 | �²³ | 1 |
1593 | �²·min� | 4 |
1594 | �²¹ | 3 |
1595 | �²•2 | 3 |
1596 | �²� | 1 |
1597 | �³ | 34 |
1598 | �³/ml | 4 |
1599 | �³ca | 1 |
1600 | �³eseekawqklcsl¹� | 1 |
1601 | �³sm | 1 |
1602 | �³₃system | 1 |
1603 | �¹ | 1,165 |
1604 | �¹.day� | 1 |
1605 | �¹.min� | 2 |
1606 | �¹.m� | 2 |
1607 | �¹/μu/ml | 2 |
1608 | �¹dhs | 1 |
1609 | �¹h� | 1 |
1610 | �¹l | 1 |
1611 | �¹min� | 1 |
1612 | �¹pmol� | 1 |
1613 | �¹sec� | 1 |
1614 | �¹thallium | 1 |
1615 | �¹tl | 5 |
1616 | �¹² | 5 |
1617 | �¹·1.73 | 8 |
1618 | �¹·day� | 4 |
1619 | �¹·d� | 10 |
1620 | �¹·h� | 7 |
1621 | �¹·min·� | 3 |
1622 | �¹·min� | 34 |
1623 | �¹·ml� | 4 |
1624 | �¹·wk� | 2 |
1625 | �¹¹ | 3 |
1626 | �¹×d� | 1 |
1627 | �¹×h� | 1 |
1628 | �¹•d� | 3 |
1629 | �¹∙day� | 4 |
1630 | �¹∶120 | 2 |
1631 | �¹� | 6 |
1632 | �π | 1 |
1633 | �• | 1 |
1634 | �₅₀ | 3 |
1635 | �₅₀-value | 1 |
1636 | �₋yb³� | 1 |
1637 | �� | 178 |
1 | anti-tnf- | 4 |
2 | ₃- | 1 |
3 | �- | 1 |
4 | +/ | 25 |
5 | fa/ | 1 |
6 | //www.hus.fi/ | 1 |
7 | www.karger.com/ | 1 |
8 | p,0 | 1 |
9 | //www.clinicaltrials.gov/ct2/show/nct00106210 | 1 |
10 | //clinicaltrials.gov/ct2/show/nct00206310 | 1 |
11 | =-0.610 | 1 |
12 | //clinicaltrials.gov/ct2/show/nct01880710 | 1 |
13 | actrn=12611000081910 | 1 |
14 | take10 | 2 |
15 | �10 | 1 |
16 | �¹∶120 | 2 |
17 | proj=3820 | 1 |
18 | tc=820 | 1 |
19 | �20 | 1 |
20 | =-0.230 | 1 |
21 | �30 | 1 |
22 | =-0.740 | 1 |
23 | 1d=450 | 1 |
24 | tau50 | 3 |
25 | //clinicaltrials.gov/ct/show/nct00338260 | 3 |
26 | nct00643760 | 1 |
27 | =0.58-0.80 | 1 |
28 | =0.680 | 1 |
29 | →0 | 1 |
30 | term=exist-1 | 1 |
31 | 60.3±54.1 | 1 |
32 | term=cer-001 | 1 |
33 | term=opal-hiv-1001 | 1 |
34 | �2001 | 1 |
35 | �5201 | 1 |
36 | =-0.31 | 2 |
37 | //www.clinicaltrials.gov/ct2/show/nct00380731 | 1 |
38 | id=335931 | 1 |
39 | :3.24±0.41 | 1 |
40 | tc=1351 | 1 |
41 | difference551 | 1 |
42 | =-0.61 | 1 |
43 | =0.061 | 1 |
44 | proj=2561 | 1 |
45 | //clinicaltrials.gov/ct2/show/nct01294761 | 1 |
46 | id=83071 | 1 |
47 | nct00376571 | 1 |
48 | =-0.771 | 1 |
49 | ees=0.91 | 1 |
50 | =0.191 | 2 |
51 | actrn=12609000885291 | 1 |
52 | =-0.491 | 1 |
53 | //www.clinicaltrials.gov/ct/show/nct00114491 | 1 |
54 | path=1 | 1 |
55 | order=1 | 4 |
56 | order_1 | 1 |
57 | p.met1 | 1 |
58 | �s3/2 | 1 |
59 | �i15/2 | 1 |
60 | �f9/2 | 1 |
61 | term=mtn-002 | 1 |
62 | tc=3102 | 1 |
63 | =0.502 | 1 |
64 | code=02 | 1 |
65 | term=quetiapine+112 | 1 |
66 | term=nct016301952912 | 1 |
67 | //www.clinicaltrials.gov/ct2/show/nct01952912 | 1 |
68 | trialid=drks00003322 | 1 |
69 | tc=2922 | 1 |
70 | =-0.32 | 4 |
71 | proj=2132 | 1 |
72 | =0.332 | 1 |
73 | //clinicaltrials.gov/ct2/show/nct01361932 | 1 |
74 | term=nct01361932 | 1 |
75 | actrn=12612000132842 | 1 |
76 | acc=gse38942 | 1 |
77 | =0.40-0.62 | 1 |
78 | 0.51–0.62 | 1 |
79 | 4.3134-0.0162 | 1 |
80 | id=335162 | 1 |
81 | trialid=ntr1862 | 1 |
82 | //clinicaltrials.gov/ct2/show/nct00472862 | 1 |
83 | //clinicaltrials.gov/ct2/show/nct00091962 | 2 |
84 | //clinicaltrials.gov/ct2/show/nct00338962 | 1 |
85 | =-.82 | 1 |
86 | =-0.182 | 1 |
87 | tc=1892 | 1 |
88 | and2 | 3 |
89 | �cm2 | 1 |
90 | 3p2 | 2 |
91 | 15q2 | 2 |
92 | ер2 | 2 |
93 | �²•2 | 3 |
94 | 10-3 | 26 |
95 | ×10-3 | 1 |
96 | 1.2±0.5×10-3 | 1 |
97 | //www.clinicaltrials.gov/ct2/show/nct00835003 | 1 |
98 | term=nct00835003 | 1 |
99 | tc=2303 | 1 |
100 | =0.603 | 1 |
101 | tc=703 | 1 |
102 | id=81803 | 1 |
103 | //www.clinicaltrials.gov/ct/show/nct00344513 | 1 |
104 | id=335613 | 1 |
105 | //clinicaltrials.gov/ct2/show/nct01154023 | 1 |
106 | tc=1123 | 1 |
107 | ₅=18.33 | 1 |
108 | tc=2233 | 1 |
109 | =-0.43 | 2 |
110 | //clinicaltrials.gov/ct2/show/nct00849043 | 1 |
111 | =-0.143 | 1 |
112 | id=336143 | 1 |
113 | //clinicaltrials.gov/ct2/show/nct00789243 | 1 |
114 | term=nct00789243 | 1 |
115 | //clinicaltrials.gov/ct/show/nct00132743 | 1 |
116 | //clinicaltrials.gov/ct2/show/nct01386853 | 1 |
117 | term=nct01386853 | 1 |
118 | ct2/show/nct00931463 | 1 |
119 | id=335463 | 1 |
120 | //clinicaltrials.gov/ct2/show/nct01556763 | 1 |
121 | term=nct01556763 | 1 |
122 | �¹·1.73 | 8 |
123 | =-0·73 | 1 |
124 | =0·73 | 1 |
125 | -983 | 1 |
126 | //www.clinicaltrials.gov/ct2/show/nct00466193 | 1 |
127 | tc=2993 | 1 |
128 | //www.clinicaltrials.gov/ct/show/nct00174993 | 1 |
129 | chcf3 | 2 |
130 | py3 | 1 |
131 | 27.8±12.4 | 1 |
132 | 7,904 | 2 |
133 | proj=3904 | 1 |
134 | =0.224 | 1 |
135 | //www.clinicaltrials.gov/ct2/show/nct00090324 | 1 |
136 | //www.clinicaltrials.gov/ct2/show/nct00772044 | 1 |
137 | www.clinicaltrials.gov/ct/show/nct00194454 | 1 |
138 | tc=854 | 1 |
139 | actrn=12611000951954 | 1 |
140 | id=crd42013004364 | 1 |
141 | id=308074 | 1 |
142 | =-0·74 | 1 |
143 | proj=2384 | 1 |
144 | id=343384 | 1 |
145 | tc=2584 | 1 |
146 | �hctz37.5 | 4 |
147 | �=0.05 | 1 |
148 | id=362005 | 1 |
149 | //www.clinicaltrials.gov/ct2/show/nct00540605 | 1 |
150 | id=335115 | 1 |
151 | ct2/show/nct00528515 | 1 |
152 | �15 | 1 |
153 | �cd25 | 5 |
154 | �hctz25 | 3 |
155 | =5.35 | 1 |
156 | id=335135 | 1 |
157 | tc=3045 | 1 |
158 | event_id=445 | 1 |
159 | tc=1155 | 1 |
160 | =-0.65 | 1 |
161 | tc=2665 | 1 |
162 | trialid=actrn12611001256965 | 1 |
163 | doi=363175 | 1 |
164 | studyid=7285 | 1 |
165 | =-0.295 | 1 |
166 | �5 | 1 |
167 | term=spd489-306 | 1 |
168 | tc=3116 | 2 |
169 | 6.3640-0.0316 | 1 |
170 | term=nct01157416 | 1 |
171 | =-0.716 | 1 |
172 | tc=2126 | 1 |
173 | -226 | 2 |
174 | //www.clinicaltrials.gov/ct2/show/nct02051426 | 1 |
175 | term=nct02051426 | 1 |
176 | tc=1836 | 1 |
177 | ≥.56 | 1 |
178 | =0.556 | 1 |
179 | //clinicaltrials.gov/ct2/show/nct01384656 | 1 |
180 | difference56 | 1 |
181 | trialid=actrn12610000257066 | 1 |
182 | //clinicaltrials.gov/ct2/show/nct01447966 | 1 |
183 | term=nct00371176 | 1 |
184 | tc=1576 | 1 |
185 | //clinicaltrials.gov/ct2/show/nct00611286 | 1 |
186 | proj=3486 | 1 |
187 | tc=1786 | 1 |
188 | =0.91-0.96 | 1 |
189 | tc=3396 | 1 |
190 | tc=3596 | 1 |
191 | tc=1696 | 1 |
192 | kg/1.7 | 1 |
193 | 0.4±185.7 | 1 |
194 | tc=3007 | 1 |
195 | =-0.207 | 1 |
196 | =0.207 | 1 |
197 | snapshotid=13617948230017 | 1 |
198 | =-0.217 | 1 |
199 | difference517 | 1 |
200 | �cd127 | 1 |
201 | //clinicaltrials.gov/ct2/show/nct00562627 | 1 |
202 | trialid=cuhk_cct00037 | 1 |
203 | //clinicaltrials.gov/ct2/show/nct01201837 | 1 |
204 | tc=3147 | 1 |
205 | tc=467 | 1 |
206 | id=83667 | 1 |
207 | tc=1867 | 1 |
208 | tc=3377 | 1 |
209 | snapshotid=13617947952577 | 1 |
210 | =0.677 | 1 |
211 | tc=2297 | 2 |
212 | id=7 | 1 |
213 | ₆h₉o7 | 1 |
214 | 0.6±1.8 | 1 |
215 | �/l-5.8 | 1 |
216 | id=308008 | 1 |
217 | //clinicaltrials.gov/ct2/show/nct01178008 | 1 |
218 | //clinicaltrials.gov/ct2/show/nct01141608 | 1 |
219 | tc=2018 | 1 |
220 | proj=1618 | 1 |
221 | 1.10-5.28 | 1 |
222 | =0.628 | 1 |
223 | //clinicaltrials.gov/ct2/show/nct00789828 | 1 |
224 | 0.92+0.38 | 1 |
225 | studyid=13538 | 1 |
226 | =0.638 | 1 |
227 | =-.58 | 1 |
228 | tc=2058 | 1 |
229 | studyid=4058 | 1 |
230 | =0.658 | 2 |
231 | //clinicaltrials.gov/ct/show/nct00043758 | 1 |
232 | tc=2168 | 2 |
233 | id=crd42011001468 | 1 |
234 | //www.clinicaltrials.gov/ct2/show/nct00764868 | 1 |
235 | id=25178 | 1 |
236 | //clinicaltrials.gov/ct2/show/nct00088478 | 1 |
237 | //clinicaltrials.gov/ct2/show/nct00609778 | 1 |
238 | id=82878 | 1 |
239 | id=82978 | 1 |
240 | trialid=actrn12610000958088 | 1 |
241 | tc=3288 | 1 |
242 | srch=isrctn84130388 | 1 |
243 | //clinicaltrials.gov/ct2/show/nct01398488 | 1 |
244 | //www.clinicaltrials.gov/ct2/show/nct00449488 | 1 |
245 | id=81688 | 1 |
246 | term=00863798 | 1 |
247 | //clinicaltrials.gov/ct2/show/nct00863798 | 1 |
248 | 2.9±3.9 | 1 |
249 | 274.9 | 2 |
250 | id=82509 | 1 |
251 | actrn=12611000929909 | 1 |
252 | :3.72±0.19 | 1 |
253 | =0.019 | 1 |
254 | id=343019 | 1 |
255 | term=nct01157429 | 1 |
256 | tc=1639 | 1 |
257 | //clinicaltrials.gov/ct2/show/nct00693849 | 1 |
258 | id=362949 | 1 |
259 | =-0.159 | 1 |
260 | id=82159 | 1 |
261 | id=335159 | 1 |
262 | �x+17075.659 | 1 |
263 | tc=4169 | 1 |
264 | cdrid=68869 | 1 |
265 | //clinicaltrials.gov/ct2/show/nct02016079 | 1 |
266 | =0.379 | 1 |
267 | studyid=10479 | 1 |
268 | //clinicaltrials.gov/ct2/show/nct00501579 | 1 |
269 | id=347879 | 1 |
270 | =-.89 | 1 |
271 | q=39629189 | 1 |
272 | //www.isrctn.com/isrctn39629189 | 1 |
273 | =-0.389 | 1 |
274 | id=362489 | 1 |
275 | id=347799 | 1 |
276 | -da1a | 2 |
277 | -y113a | 1 |
278 | rnica | 9 |
279 | �²ca | 1 |
280 | �³ca | 1 |
281 | �ca | 4 |
282 | -pka-nmda | 1 |
283 | nakanda | 1 |
284 | �c-urea | 1 |
285 | �-urea | 1 |
286 | �ga | 16 |
287 | �dha | 1 |
288 | protezama | 1 |
289 | enchondroma | 1 |
290 | term=corona | 1 |
291 | rjuna | 1 |
292 | �na | 1 |
293 | glcnac₂-pa | 5 |
294 | nau/whakapapa | 1 |
295 | �mdc-ra | 1 |
296 | sasa | 16 |
297 | o-b | 3 |
298 | term=gik+and+opcab | 1 |
299 | g/lb | 3 |
300 | ₆₅b | 6 |
301 | �ga-nodaga-c | 1 |
302 | →cc | 1 |
303 | �-thc | 16 |
304 | �-tetrahydrocannabinol/thc | 1 |
305 | ori/non-pacific | 1 |
306 | �-iminodiacetic | 1 |
307 | brinolytic | 1 |
308 | term=linc | 1 |
309 | �mtc | 5 |
310 | ₀₀c | 1 |
311 | �c | 34 |
312 | ₀/d | 1 |
313 | �-thc-induced | 1 |
314 | ₋₃₅-induced | 2 |
315 | �-induced | 6 |
316 | spreaded | 1 |
317 | �-linked | 1 |
318 | �-evoked | 4 |
319 | �ga-labeled | 3 |
320 | �c-labeled | 2 |
321 | �tc-extametazime-labeled | 1 |
322 | �cu-labeled | 1 |
323 | ₆-labeled | 1 |
324 | �i-radiolabeled | 1 |
325 | dazzled | 1 |
326 | rmed | 2 |
327 | gure-of-8-shaped | 1 |
328 | �-doped | 2 |
329 | �-codoped | 4 |
330 | �-triggered | 1 |
331 | mpowered | 1 |
332 | am-treated | 3 |
333 | �-related | 1 |
334 | a-stimulated | 7 |
335 | ₋₂₄-stimulated | 2 |
336 | �-activated | 3 |
337 | �selected | 1 |
338 | �-depleted | 1 |
339 | growed | 1 |
340 | xed | 2 |
341 | �f-galacto-rgd | 1 |
342 | �cu-raft-rgd | 6 |
343 | `id | 1 |
344 | ṣid | 1 |
345 | �d-child | 1 |
346 | ₄and | 1 |
347 | lifestyle/mind | 1 |
348 | .ultrasound | 1 |
349 | term=social+anxiety+cognitive+behavioral+therapy+stanford | 1 |
350 | �d | 2 |
351 | �be | 2 |
352 | ndice | 1 |
353 | cance | 4 |
354 | �-glucuronide | 1 |
355 | �f-fluoride | 2 |
356 | �fe | 5 |
357 | clairage | 1 |
358 | dødelige | 1 |
359 | saludable | 2 |
360 | �-permeable | 1 |
361 | uncombinable | 1 |
362 | “myelomeningocele | 1 |
363 | ene | 3 |
364 | �f-nifene | 1 |
365 | �f-nifrolene | 7 |
366 | monoene | 1 |
367 | citabine | 1 |
368 | �f-nifrolidine | 2 |
369 | �f-nifzetidine | 2 |
370 | �codeine | 1 |
371 | 'medline | 1 |
372 | �-aminopropylspermine | 1 |
373 | �-alkylguanine | 1 |
374 | /arginine | 1 |
375 | �-benzyladenine-type | 1 |
376 | ₃-type | 1 |
377 | term=spare | 1 |
378 | term=postpartum+acupuncture | 1 |
379 | �/calmodulin-kinase | 1 |
380 | �-atpase | 13 |
381 | �atpase | 1 |
382 | term=stimulant+reduction+intervention+using+dosed+exercise | 1 |
383 | �f-fluoro-2-deoxy-d-glucose | 1 |
384 | �/d-glucose | 1 |
385 | �f-fluorodeoxy-glucose | 1 |
386 | �fluoro-deoxyglucose | 1 |
387 | �f-fluorodeoxyglucose | 3 |
388 | ¡cuídate | 2 |
389 | �/taurocholate | 1 |
390 | �₅₀-value | 1 |
391 | _nfpb=true | 1 |
392 | ₃f | 1 |
393 | �f | 11 |
394 | �g/g | 1 |
395 | hemoglobin/g | 1 |
396 | �i-f-hbsag | 1 |
397 | �i-h-hbsag | 1 |
398 | term=rollman+cabg | 2 |
399 | �f-fdg | 2 |
400 | �fdg | 1 |
401 | =8660kg | 1 |
402 | �kg | 4 |
403 | �-mg | 3 |
404 | �mg | 2 |
405 | term=spreng | 1 |
406 | �-binding | 3 |
407 | �-encoding | 1 |
408 | �itching | 1 |
409 | r-blocking | 1 |
410 | �ga-labeling | 2 |
411 | 14-ring | 1 |
412 | �-conducting | 1 |
413 | �-secreting | 2 |
414 | term=ocd+and+st+petersburg | 1 |
415 | ₉₂g | 1 |
416 | 1g/m2/h | 1 |
417 | ch-ch | 1 |
418 | �/nadh | 3 |
419 | choh | 3 |
420 | �mtc-lp-cooh | 2 |
421 | auc₀₋₄h | 2 |
422 | �h | 2 |
423 | �mtc-sestamibi | 1 |
424 | |midi | 1 |
425 | //www.ncbi.nlm.nih.gov/geo/query/acc.cgi | 1 |
426 | //upload.umin.ac.jp/cgi-open-bin/ctr/ctr.cgi | 3 |
427 | mikimiki | 3 |
428 | posadzki | 1 |
429 | həli | 1 |
430 | -pi | 5 |
431 | ori | 142 |
432 | df/emtri | 1 |
433 | preschool-si | 1 |
434 | �si | 5 |
435 | �i | 10 |
436 | kermak | 1 |
437 | �week | 1 |
438 | �k | 3 |
439 | �p*l | 1 |
440 | �/l | 47 |
441 | term=ventus+medical | 1 |
442 | �nanimal | 2 |
443 | genre=journal | 2 |
444 | �total | 1 |
445 | �al | 6 |
446 | forum/wikipathways-devel | 1 |
447 | �t-cell | 1 |
448 | μl/well | 3 |
449 | �g/ml | 1 |
450 | ₀copies/ml | 1 |
451 | ₀iu/ml | 1 |
452 | �¹/μu/ml | 2 |
453 | �³/ml | 4 |
454 | �/ml | 3 |
455 | //www.controlled-trials.com/isrctn/search.html | 1 |
456 | navigationid=trial.html | 2 |
457 | //e-irb.khmccri.or.kr/eirb/receipt/index.html | 1 |
458 | �ml | 4 |
459 | -protocol | 1 |
460 | �-tetrahydrocannabinol | 10 |
461 | �salmeterol | 2 |
462 | �¹tl | 5 |
463 | �-2-methyl-oxodienyl | 2 |
464 | trienyl | 2 |
465 | monoenyl | 1 |
466 | �¹l | 1 |
467 | �/μl | 4 |
468 | 1.8-m | 3 |
469 | choornam | 3 |
470 | �³₃system | 1 |
471 | term=neurocom | 1 |
472 | atheism | 1 |
473 | �³sm | 1 |
474 | �¹thallium | 1 |
475 | �m | 1 |
476 | adrian | 1 |
477 | �span | 2 |
478 | �-ocn | 2 |
479 | medizinischen | 9 |
480 | bien | 5 |
481 | stufenverfahren | 1 |
482 | rehabilitationsverfahren | 1 |
483 | �-osteocalcin | 1 |
484 | ₅min | 2 |
485 | �min | 4 |
486 | -actinin | 1 |
487 | b/angiotensin | 1 |
488 | �i-echistatin | 1 |
489 | �gln | 4 |
490 | ₈-column | 1 |
491 | term=sirion | 1 |
492 | term=desipramine+and+alcohol+dependence+and+depression | 1 |
493 | term=international+study+to+predict+optimized+treatment+for+depression | 1 |
494 | term=gottlieb+tablet+pc+education | 1 |
495 | ltration | 1 |
496 | �mobilization | 1 |
497 | nization | 2 |
498 | “infection | 1 |
499 | �f-fluorodeoxyglucose-positron | 1 |
500 | ín | 1 |
501 | �n | 18 |
502 | amico | 1 |
503 | //drks-neu.uniklinik-freiburg.de/drks_web/navigate.do | 2 |
504 | chcho | 4 |
505 | lozano | 1 |
506 | �no | 2 |
507 | �-3-keto | 2 |
508 | ₈h₂o | 1 |
509 | �ga-trap | 3 |
510 | order=1cp | 1 |
511 | ₋₃/dp | 1 |
512 | ₂-adp | 1 |
513 | //education.amjmed.com/video.php | 1 |
514 | //diagnosticpathology.slidepath.com/dih/webviewer.php | 2 |
515 | //elearning.facs.org/mod/resource/view.php | 1 |
516 | //mht.mis.nchu.edu.tw/moodle/course/view.php | 1 |
517 | //hvpmalaysia.kk.usm.my/mhgvc/index.php | 1 |
518 | www.crd.york.ac.uk/prospero/display_record.asp | 1 |
519 | //www.crd.york.ac.uk/prospero/display_record.asp | 1 |
520 | //taylorandfrancis.metapress.com/openurl.asp | 2 |
521 | www.trialregister.nl/trialreg/admin/rctview.asp | 2 |
522 | //www.trialregister.nl/trialreg/admin/rctview.asp | 38 |
523 | c-n-r | 1 |
524 | alpha2c-ar | 1 |
525 | �cr | 7 |
526 | �gender | 4 |
527 | wissenschaftlicher | 1 |
528 | mujer | 4 |
529 | о₂greater | 1 |
530 | id=register | 1 |
531 | �f-nmr | 1 |
532 | �si-nmr | 2 |
533 | good/good/fair/poor | 1 |
534 | �-sensor | 1 |
535 | �or | 2 |
536 | �i-ttr | 1 |
537 | yana-s | 1 |
538 | �/s | 2 |
539 | �cs | 38 |
540 | �-modes | 1 |
541 | -relaxivities | 1 |
542 | -lactamases | 1 |
543 | participant-witnesses | 1 |
544 | bolites | 1 |
545 | �¹dhs | 1 |
546 | �homeostasis | 1 |
547 | brosis | 1 |
548 | �ga-radiopharmaceuticals | 1 |
549 | �-ms/ms | 1 |
550 | �-hrms/ms | 3 |
551 | �iams | 2 |
552 | ₀/grams | 1 |
553 | -catenins | 1 |
554 | �-ions | 1 |
555 | �mnps | 1 |
556 | �elders | 1 |
557 | fast-food/burgers | 1 |
558 | term=voors | 1 |
559 | forum/wikipathways-discuss | 1 |
560 | ₋₄-subunits | 1 |
561 | term=behavioral+intervention+for+insomnia+in+older+adults | 1 |
562 | www.clinicaltrials.gov/ct2/results | 1 |
563 | //www.clinicaltrials.gov/ct2/results | 1 |
564 | //clinicaltrials.gov/ct2/results | 2 |
565 | outcasts | 1 |
566 | broblasts | 1 |
567 | transform-us | 5 |
568 | term=mauritius | 1 |
569 | term=ventus | 1 |
570 | function=brows | 3 |
571 | �s | 17 |
572 | yat | 1 |
573 | single-object | 1 |
574 | �ndiet | 2 |
575 | blicket | 1 |
576 | �f-fluorodeoxyglucose-pet | 1 |
577 | �f-pet | 4 |
578 | �fdg-pet | 1 |
579 | -subunit | 5 |
580 | cant | 30 |
581 | ₂-dependent | 1 |
582 | �-dependent | 3 |
583 | �-independent | 2 |
584 | cient | 3 |
585 | �management | 1 |
586 | �n-enrichment | 1 |
587 | �point | 1 |
588 | term=olanzapine+depot | 1 |
589 | eurekalert | 1 |
590 | eucharist | 1 |
591 | lacalut | 2 |
592 | �t | 1 |
593 | nilavembu | 4 |
594 | �cfu | 1 |
595 | haku | 1 |
596 | kaku | 1 |
597 | hoku | 2 |
598 | 'temu | 2 |
599 | honzou | 1 |
600 | �u | 6 |
601 | whether/how | 1 |
602 | ndex | 1 |
603 | //apps.who.int/trialsearch/trial2.aspx | 1 |
604 | //www.cct.cuhk.edu.hk/registry/publictrialrecord.aspx | 1 |
605 | //apps.who.int/trialsearch/trial.aspx | 4 |
606 | //public.ukcrn.org.uk/search/studydetail.aspx | 4 |
607 | //www.cancer.gov/search/viewclinicaltrials.aspx | 1 |
608 | //www.moh.gov.sg/mohcorp/publications.aspx | 1 |
609 | www.anzctr.org.au/trial_view.aspx | 1 |
610 | //www.anzctr.org.au/trial_view.aspx | 14 |
611 | //www.anzctr.org.au/registry/trial_review.aspx | 2 |
612 | //www.anzctr.org.au/trial/registration/trialreview.aspx | 13 |
613 | //www.chictr.org/cn/proj/show.aspx | 2 |
614 | //www.chictr.org/en/proj/show.aspx | 5 |
615 | �-influx | 1 |
616 | �cfu/animal/day | 1 |
617 | �day | 5 |
618 | ciency | 1 |
619 | term=prodigy | 1 |
620 | legibly | 1 |
621 | cantly | 22 |
622 | term=hysterectomy | 1 |
623 | sorry | 6 |
624 | //www.pactr.org/atmweb/appmanager/atm/atmregistry | 1 |
625 | fiury | 1 |
626 | -relaxivity | 3 |
627 | zjaz | 3 |
628 | lvarez | 1 |
629 | �hctz | 5 |
630 | ₀ | 116 |
631 | a₀ | 1 |
632 | �d₀ | 1 |
633 | ₀₀ | 6 |
634 | ₂₀ | 4 |
635 | ₋₂₀ | 1 |
636 | ₋₄₀ | 1 |
637 | �₅₀ | 3 |
638 | ₈₀ | 2 |
639 | �π | 1 |
640 | ₂ | 163 |
641 | ₈.₂ | 1 |
642 | /₂ | 7 |
643 | →²f₇/₂ | 1 |
644 | �n₂ | 1 |
645 | �co₂ | 2 |
646 | �/tio₂ | 1 |
647 | h₂₉n₃o₂ | 1 |
648 | -s₂ | 1 |
649 | �s₂ | 1 |
650 | /mt₂ | 1 |
651 | �t₂ | 1 |
652 | ₆-c₂₂ | 1 |
653 | ₄₂ | 1 |
654 | ₋₄₂ | 3 |
655 | ₉₂ | 2 |
656 | γ₂ | 5 |
657 | /₃nb₂/₃ | 1 |
658 | .₅te₃ | 3 |
659 | -xkxbio₃ | 3 |
660 | �-wo₃ | 1 |
661 | -xtixo₃ | 2 |
662 | ₉-c₂₃ | 1 |
663 | ₋₃₆₃ | 2 |
664 | ₀₄₋₃₆₃ | 8 |
665 | ₋₃ | 1 |
666 | x̃ | 12 |
667 | �f₄ | 1 |
668 | ₃co₄ | 3 |
669 | -x₄ | 1 |
670 | ₀₆₋₃₂₄ | 4 |
671 | ₋₂₄ | 6 |
672 | ₋₄ | 2 |
673 | ₅ | 18 |
674 | ₋₃₅ | 3 |
675 | ₆ | 24 |
676 | �-cp₃o₆ | 1 |
677 | ₇ | 26 |
678 | ₉₇ | 14 |
679 | ević | 1 |
680 | ₈ | 5 |
681 | ₃.₈ | 4 |
682 | �i₈ | 1 |
683 | ₆₈ | 1 |
684 | ₉ | 7 |
685 | o₃₉ | 4 |
686 | 瘀胶囊 | 1 |
687 | 春胶囊 | 1 |
688 | �• | 1 |
689 | cardean™ | 1 |
690 | jué | 1 |
691 | nī | 2 |
692 | xī | 1 |
693 | ryū | 1 |
694 | †| 1 |
695 | shí | 2 |
696 | 湯 | 1 |
697 | ii° | 3 |
698 | �/m² | 1 |
699 | 10¹² | 1 |
700 | �¹² | 5 |
701 | �² | 68 |
702 | 潜阳 | 1 |
703 | �²³ | 1 |
704 | �³ | 34 |
705 | β₂γ | 1 |
706 | o₃₋δ | 1 |
707 | ₈h₂₉o₂· | 1 |
708 | �²¹ | 3 |
709 | 10¹¹ | 5 |
710 | �¹¹ | 3 |
711 | �¹ | 1,165 |
712 | fú | 2 |
713 | ódź | 8 |
714 | /μ | 1 |
715 | � | 2,038 |
716 | life'� | 1 |
717 | costs'� | 1 |
718 | re=v*d*� | 1 |
719 | +� | 2 |
720 | -� | 1 |
721 | tnf-� | 2 |
722 | factor-� | 1 |
723 | possible.� | 1 |
724 | sure.� | 1 |
725 | temperature.� | 1 |
726 | disease.� | 1 |
727 | use.� | 1 |
728 | aging.� | 1 |
729 | whom.� | 1 |
730 | saffron.� | 1 |
731 | “pleasant.� | 1 |
732 | know.� | 1 |
733 | “luxury.� | 1 |
734 | yb₀.� | 1 |
735 | bi₀.₉gd₀.� | 2 |
736 | nicu-bazr₀.� | 1 |
737 | ce₀.₇y₀.� | 1 |
738 | �.� | 1 |
739 | /� | 2 |
740 | �/� | 40 |
741 | 0.0� | 1 |
742 | 31.0� | 1 |
743 | 2000� | 1 |
744 | los100� | 3 |
745 | 10� | 215 |
746 | /10� | 2 |
747 | 182.2/10� | 1 |
748 | µm/10� | 1 |
749 | sfcs/10� | 1 |
750 | cases/10� | 1 |
751 | mutants/10� | 1 |
752 | lu/10� | 1 |
753 | /il10� | 1 |
754 | aom/il10� | 1 |
755 | -0.01x10� | 1 |
756 | 3x10� | 1 |
757 | 4x10� | 1 |
758 | +0.16x10� | 1 |
759 | ≈10� | 1 |
760 | ×10� | 11 |
761 | 1.0×10� | 2 |
762 | 5.0×10� | 1 |
763 | 100×10� | 1 |
764 | 50-100×10� | 1 |
765 | 30×10� | 1 |
766 | 50×10� | 1 |
767 | 150×10� | 1 |
768 | 80×10� | 1 |
769 | 30-80×10� | 1 |
770 | 5.90×10� | 1 |
771 | 1×10� | 5 |
772 | 5.1×10� | 1 |
773 | 10.2×10� | 1 |
774 | �²-12.2×10� | 1 |
775 | 3×10� | 1 |
776 | 1.3×10� | 1 |
777 | p=1.3×10� | 1 |
778 | ≤1.3×10� | 1 |
779 | 2.13×10� | 1 |
780 | 6.33×10� | 1 |
781 | y=5.873×10� | 1 |
782 | 8.4×10� | 1 |
783 | 5×10� | 2 |
784 | 0.5×10� | 1 |
785 | 3.5×10� | 1 |
786 | 25×10� | 1 |
787 | ≤125×10� | 1 |
788 | catenatum+0.75×10� | 1 |
789 | 1.96×10� | 1 |
790 | �²-9.7×10� | 1 |
791 | +17×10� | 1 |
792 | 9.8×10� | 1 |
793 | 2.9×10� | 2 |
794 | ≥10� | 1 |
795 | p=1.1´10� | 1 |
796 | p=5.2´10� | 1 |
797 | p=2.9´10� | 1 |
798 | p=6.9´10� | 1 |
799 | ∼10� | 1 |
800 | 20� | 1 |
801 | 30� | 1 |
802 | los150� | 4 |
803 | pd-1� | 5 |
804 | endothelin-1� | 1 |
805 | �gr-1� | 1 |
806 | et-1� | 8 |
807 | nhxyn11� | 4 |
808 | re-nhxyn11� | 3 |
809 | 16-21� | 1 |
810 | cd31� | 2 |
811 | 0.41� | 1 |
812 | �/41� | 2 |
813 | -0.91� | 1 |
814 | a1� | 11 |
815 | �/sca1� | 1 |
816 | r1� | 2 |
817 | cx₃cr1� | 4 |
818 | s1� | 1 |
819 | kir2dl1/s1� | 1 |
820 | ros1� | 1 |
821 | t1� | 9 |
822 | gpat1� | 6 |
823 | 2� | 5 |
824 | -2� | 1 |
825 | her-2� | 1 |
826 | 6.2� | 1 |
827 | tie2� | 2 |
828 | ch2� | 6 |
829 | p2� | 14 |
830 | ²-p2� | 1 |
831 | �/vegfr2� | 2 |
832 | �/kir2dl2/l3/s2� | 1 |
833 | lag-3� | 2 |
834 | tim-3� | 3 |
835 | cd103� | 3 |
836 | p23� | 3 |
837 | �-33� | 1 |
838 | cd133� | 2 |
839 | p53� | 3 |
840 | cd163� | 2 |
841 | cd3� | 17 |
842 | �/cd3� | 1 |
843 | jak3� | 2 |
844 | clstn3� | 1 |
845 | foxp3� | 4 |
846 | �foxp3� | 4 |
847 | ctla-4� | 4 |
848 | il-4� | 1 |
849 | 6.4� | 1 |
850 | cd14� | 16 |
851 | cd24� | 2 |
852 | �cd24� | 1 |
853 | cd34� | 1 |
854 | �/cd34� | 2 |
855 | cd144� | 2 |
856 | cd4� | 129 |
857 | �cd4� | 2 |
858 | i4� | 1 |
859 | 23.5� | 1 |
860 | 7.5� | 3 |
861 | 15� | 1 |
862 | cd25� | 4 |
863 | �cd25� | 5 |
864 | 6.6� | 1 |
865 | cd16� | 4 |
866 | cd14+cd16� | 1 |
867 | �/cd16� | 1 |
868 | �cd16� | 5 |
869 | 36� | 1 |
870 | -0.56� | 1 |
871 | �cd56� | 6 |
872 | c6� | 1 |
873 | car6� | 2 |
874 | �-17� | 1 |
875 | cd27� | 3 |
876 | ccr7� | 1 |
877 | 31.8� | 1 |
878 | 38� | 1 |
879 | cd138� | 1 |
880 | cd68� | 1 |
881 | cd8� | 41 |
882 | �t/cd8� | 1 |
883 | �/cd8� | 6 |
884 | �cd8� | 2 |
885 | 9� | 1 |
886 | 6.9� | 1 |
887 | cd19� | 3 |
888 | ps19� | 3 |
889 | 39� | 3 |
890 | �-39� | 1 |
891 | cd39� | 1 |
892 | -0.69� | 1 |
893 | 10^� | 2 |
894 | a� | 37 |
895 | �/a� | 4 |
896 | �/cd1a� | 1 |
897 | 4a� | 3 |
898 | ba� | 3 |
899 | hba� | 34 |
900 | sca� | 14 |
901 | bifida� | 1 |
902 | ga� | 1 |
903 | pga� | 7 |
904 | alpha� | 7 |
905 | bia� | 1 |
906 | ataxia� | 1 |
907 | la� | 8 |
908 | na� | 39 |
909 | drug-na� | 3 |
910 | insulin-na� | 2 |
911 | treatment-na� | 2 |
912 | zebra� | 1 |
913 | delta� | 2 |
914 | sta� | 1 |
915 | ₉₂-sta� | 3 |
916 | b� | 45 |
917 | hla-b� | 1 |
918 | m-b� | 4 |
919 | o-b� | 3 |
920 | cd11b� | 2 |
921 | 4b� | 2 |
922 | ab� | 1 |
923 | cab� | 1 |
924 | cb� | 17 |
925 | fb� | 17 |
926 | n-acyl-fb� | 2 |
927 | o-acyl-fb� | 1 |
928 | n-oleoyl-fb� | 1 |
929 | 3-o-oleoyl-fb� | 1 |
930 | 5-o-oleoyl-fb� | 1 |
931 | n-linoleoyl-fb� | 1 |
932 | 3-o-linoleoyl-fb� | 1 |
933 | 5-o-linoleoyl-fb� | 1 |
934 | n-palmitoyl-fb� | 3 |
935 | 3-o-palmitoyl-fb� | 1 |
936 | 5-o-palmitoyl-fb� | 1 |
937 | afb� | 10 |
938 | efb� | 2 |
939 | rb� | 4 |
940 | bi₀.₅sb� | 3 |
941 | tb� | 4 |
942 | x³b� | 1 |
943 | c� | 23 |
944 | d3-c� | 1 |
945 | b-c� | 2 |
946 | sb-c� | 1 |
947 | iso-c� | 1 |
948 | anteiso-c� | 1 |
949 | /c� | 1 |
950 | cd11c� | 1 |
951 | cd1c� | 3 |
952 | d-cd1c� | 1 |
953 | 4c� | 2 |
954 | sec� | 3 |
955 | �¹sec� | 1 |
956 | “patient-specific� | 1 |
957 | mc� | 1 |
958 | �/mc� | 4 |
959 | nc� | 1 |
960 | vanc� | 8 |
961 | src� | 13 |
962 | fuc� | 3 |
963 | c₂c� | 2 |
964 | å³.°c� | 1 |
965 | ¹³c� | 9 |
966 | ∼c� | 1 |
967 | d� | 50 |
968 | dopamine-d� | 2 |
969 | ham-d� | 14 |
970 | �/nkg2d� | 2 |
971 | nad� | 29 |
972 | tgenr-nad� | 2 |
973 | identified� | 1 |
974 | “unclosed� | 1 |
975 | refused� | 1 |
976 | “preactivated� | 1 |
977 | �reviewed� | 1 |
978 | hid� | 1 |
979 | solid� | 1 |
980 | “opioid� | 1 |
981 | β-amyloid� | 1 |
982 | wild� | 1 |
983 | “real-world� | 1 |
984 | hamd� | 4 |
985 | and� | 2 |
986 | bound� | 1 |
987 | background� | 1 |
988 | “good� | 6 |
989 | likelihood� | 1 |
990 | pd� | 1 |
991 | standard� | 1 |
992 | hrsd� | 4 |
993 | ce₂o₃d� | 1 |
994 | dγ∕d� | 1 |
995 | �¹×d� | 1 |
996 | �¹•d� | 3 |
997 | g·d� | 5 |
998 | mg·d� | 4 |
999 | h·d� | 2 |
1000 | �¹·d� | 10 |
1001 | θd� | 1 |
1002 | e� | 16 |
1003 | d'e� | 1 |
1004 | e/e� | 1 |
1005 | “hospice� | 1 |
1006 | “experience� | 1 |
1007 | de� | 5 |
1008 | decade� | 4 |
1009 | prede� | 1 |
1010 | three� | 1 |
1011 | fe� | 5 |
1012 | range� | 1 |
1013 | large� | 1 |
1014 | ₇fe₅₂ge� | 4 |
1015 | “stable� | 1 |
1016 | double� | 3 |
1017 | single� | 1 |
1018 | molecule� | 2 |
1019 | schedule� | 1 |
1020 | time� | 3 |
1021 | syndrome� | 1 |
1022 | bene� | 4 |
1023 | mirtazapine� | 1 |
1024 | oxycodone� | 7 |
1025 | apoe� | 2 |
1026 | litre� | 3 |
1027 | phase� | 1 |
1028 | exercise� | 1 |
1029 | “exercise� | 1 |
1030 | false� | 1 |
1031 | β-k₂bi₈se� | 3 |
1032 | minute� | 1 |
1033 | tissue� | 1 |
1034 | “palliative� | 1 |
1035 | f� | 36 |
1036 | cf3cf� | 1 |
1037 | ef� | 3 |
1038 | vef� | 1 |
1039 | vegf� | 6 |
1040 | tgf� | 1 |
1041 | self� | 4 |
1042 | rf� | 3 |
1043 | otf� | 1 |
1044 | g� | 64 |
1045 | sub-g� | 1 |
1046 | g₀/g� | 5 |
1047 | 100g� | 2 |
1048 | 4.5g� | 1 |
1049 | ag� | 9 |
1050 | pvp-ag� | 1 |
1051 | mag� | 1 |
1052 | fg� | 1 |
1053 | afg� | 3 |
1054 | hg� | 3 |
1055 | mahg� | 2 |
1056 | kg� | 303 |
1057 | mg.kg� | 9 |
1058 | μg.kg� | 2 |
1059 | ml.kg� | 2 |
1060 | mosm.kg� | 1 |
1061 | mgkg� | 1 |
1062 | mg×kg� | 2 |
1063 | μg×kg� | 1 |
1064 | mg∙kg� | 6 |
1065 | g•kg� | 2 |
1066 | mg•kg� | 1 |
1067 | g·kg� | 4 |
1068 | mg·kg� | 16 |
1069 | μg·kg� | 3 |
1070 | kcal·kg� | 1 |
1071 | ml·kg� | 23 |
1072 | mmol·kg� | 1 |
1073 | pmol·kg� | 6 |
1074 | mosmol·kg� | 1 |
1075 | μmol·kg� | 2 |
1076 | mosm·kg� | 1 |
1077 | n·kg� | 1 |
1078 | o₂·kg� | 2 |
1079 | �kg� | 1 |
1080 | mg� | 32 |
1081 | u·mg� | 1 |
1082 | ng� | 2 |
1083 | king� | 1 |
1084 | “cracking� | 1 |
1085 | “training� | 1 |
1086 | “fingerprinting� | 1 |
1087 | h·ng� | 4 |
1088 | log� | 28 |
1089 | pg� | 2 |
1090 | ag₃₂mpg� | 2 |
1091 | rg� | 3 |
1092 | rydberg� | 1 |
1093 | ag₃₂sg� | 3 |
1094 | x³σg� | 3 |
1095 | qìg� | 1 |
1096 | mg·g� | 6 |
1097 | μmol·g� | 1 |
1098 | μg� | 2 |
1099 | h� | 101 |
1100 | antagonist/h� | 1 |
1101 | h₃/h� | 4 |
1102 | h₅/h� | 6 |
1103 | ch� | 4 |
1104 | z-ho-ch� | 3 |
1105 | r-ch� | 5 |
1106 | -cf3ch� | 4 |
1107 | trans-cf3ch� | 2 |
1108 | -och� | 2 |
1109 | stretch� | 2 |
1110 | dh� | 1 |
1111 | adh� | 12 |
1112 | dugdh� | 1 |
1113 | high� | 4 |
1114 | “high� | 1 |
1115 | ih� | 1 |
1116 | ruih� | 1 |
1117 | nh� | 4 |
1118 | oh� | 1 |
1119 | dpph� | 1 |
1120 | rh� | 1 |
1121 | sh� | 4 |
1122 | gensh� | 1 |
1123 | acth� | 8 |
1124 | month� | 1 |
1125 | wh� | 1 |
1126 | zh� | 3 |
1127 | ₂h� | 1 |
1128 | n-c₆h� | 2 |
1129 | �¹×h� | 1 |
1130 | ²h� | 1 |
1131 | +²h� | 1 |
1132 | km·h� | 5 |
1133 | events·h� | 1 |
1134 | �¹·h� | 7 |
1135 | �¹h� | 1 |
1136 | methylation-speci� | 1 |
1137 | gender-speci� | 5 |
1138 | ibdv-speci� | 1 |
1139 | prespeci� | 1 |
1140 | modi� | 1 |
1141 | ischemia-modi� | 1 |
1142 | ji� | 2 |
1143 | li� | 1 |
1144 | ega-li� | 2 |
1145 | ampli� | 3 |
1146 | mi� | 1 |
1147 | signi� | 40 |
1148 | komeri� | 1 |
1149 | esi� | 1 |
1150 | hplc-esi� | 3 |
1151 | emulsi� | 4 |
1152 | ti� | 2 |
1153 | anti� | 1 |
1154 | identi� | 8 |
1155 | scienti� | 2 |
1156 | xi� | 2 |
1157 | j� | 3 |
1158 | tae-j� | 1 |
1159 | cd85j� | 2 |
1160 | mj� | 1 |
1161 | apj� | 1 |
1162 | k� | 51 |
1163 | �-k� | 6 |
1164 | /k� | 1 |
1165 | �/k� | 5 |
1166 | week� | 9 |
1167 | days·week� | 2 |
1168 | alk� | 1 |
1169 | nk� | 6 |
1170 | sp/nk� | 2 |
1171 | risk� | 1 |
1172 | “at-risk� | 3 |
1173 | tk� | 1 |
1174 | μvk� | 2 |
1175 | mins.wk� | 1 |
1176 | d·wk� | 2 |
1177 | �¹·wk� | 2 |
1178 | l� | 110 |
1179 | t₉-l� | 1 |
1180 | mmol.l� | 1 |
1181 | al� | 3 |
1182 | appraisal� | 1 |
1183 | cl� | 4 |
1184 | trans-chcl� | 2 |
1185 | dl� | 6 |
1186 | vldl� | 13 |
1187 | mg·dl� | 4 |
1188 | model� | 1 |
1189 | 0.06mmoll� | 1 |
1190 | 0.8mmoll� | 1 |
1191 | ml� | 133 |
1192 | ugml� | 1 |
1193 | mg·ml� | 1 |
1194 | ng·ml� | 3 |
1195 | µg·ml� | 1 |
1196 | �¹·ml� | 4 |
1197 | alcohol� | 1 |
1198 | mol� | 9 |
1199 | pmol� | 4 |
1200 | �¹pmol� | 1 |
1201 | kcal•mol� | 2 |
1202 | vol� | 2 |
1203 | sl� | 1 |
1204 | bisul� | 1 |
1205 | xyl� | 2 |
1206 | man₂xyl� | 1 |
1207 | man₃xyl� | 2 |
1208 | μmol∙h∙l� | 1 |
1209 | mg·l� | 6 |
1210 | μg·l� | 1 |
1211 | mmol·l� | 7 |
1212 | micromol·l� | 1 |
1213 | pmol·l� | 4 |
1214 | µmol·l� | 1 |
1215 | mmol·min·l� | 1 |
1216 | mu·min·l� | 1 |
1217 | meq·l� | 4 |
1218 | �l� | 8 |
1219 | m� | 158 |
1220 | people-m� | 1 |
1221 | non-m� | 22 |
1222 | kg.m� | 1 |
1223 | �¹.m� | 2 |
1224 | “program� | 1 |
1225 | sam� | 1 |
1226 | cm� | 9 |
1227 | v.cm� | 1 |
1228 | s/cm� | 1 |
1229 | dyn·s·cm� | 2 |
1230 | mm� | 2 |
1231 | kom� | 1 |
1232 | pm� | 9 |
1233 | menc-crm� | 5 |
1234 | vi-crm� | 7 |
1235 | dsm� | 3 |
1236 | cum� | 4 |
1237 | wm� | 3 |
1238 | kg•m� | 1 |
1239 | kg·m� | 2 |
1240 | m-units·m� | 3 |
1241 | mu·m� | 2 |
1242 | kv·m� | 1 |
1243 | w·m� | 6 |
1244 | n� | 16 |
1245 | -n� | 1 |
1246 | asenapine-n� | 1 |
1247 | man� | 2 |
1248 | ben� | 1 |
1249 | between� | 1 |
1250 | mitogen� | 1 |
1251 | acetaminophen� | 1 |
1252 | open� | 1 |
1253 | seven� | 1 |
1254 | ifn� | 4 |
1255 | phn� | 1 |
1256 | in� | 1 |
1257 | brain� | 1 |
1258 | protein� | 2 |
1259 | “thin� | 1 |
1260 | min� | 105 |
1261 | l.min� | 1 |
1262 | ml.min� | 1 |
1263 | �¹.min� | 2 |
1264 | ×min� | 1 |
1265 | ·min� | 1 |
1266 | l·min� | 12 |
1267 | ml·min� | 4 |
1268 | μmol·min� | 1 |
1269 | 15·l·min� | 1 |
1270 | breaths·min� | 1 |
1271 | reps·min� | 2 |
1272 | beats·min� | 6 |
1273 | w·min� | 1 |
1274 | �²·min� | 4 |
1275 | �¹·min� | 34 |
1276 | �¹min� | 1 |
1277 | on� | 1 |
1278 | con� | 9 |
1279 | min·session� | 1 |
1280 | insufflation� | 1 |
1281 | population� | 1 |
1282 | “normalization� | 1 |
1283 | “disorganization� | 1 |
1284 | action� | 1 |
1285 | recognition� | 1 |
1286 | “in-motion� | 2 |
1287 | “soft-option� | 1 |
1288 | “out-of-proportion� | 3 |
1289 | non� | 1 |
1290 | sn� | 1 |
1291 | nazn� | 2 |
1292 | ₄n� | 3 |
1293 | o� | 11 |
1294 | -o� | 1 |
1295 | cmh2o� | 8 |
1296 | placebo� | 1 |
1297 | co� | 1 |
1298 | bi₅ti₃feo� | 3 |
1299 | la₃ga₅sio� | 1 |
1300 | hko� | 4 |
1301 | onoo� | 2 |
1302 | cd45ro� | 1 |
1303 | pro� | 2 |
1304 | two� | 1 |
1305 | h₃o� | 2 |
1306 | �/h₃o� | 1 |
1307 | bi₃.₆eu₀.₄ti₃o� | 1 |
1308 | y₃ga₅o� | 2 |
1309 | ∠o� | 1 |
1310 | p� | 9 |
1311 | irbp� | 1 |
1312 | ep� | 3 |
1313 | gfp� | 1 |
1314 | kamp� | 1 |
1315 | mmp� | 1 |
1316 | pdapp� | 7 |
1317 | mpp� | 2 |
1318 | ²h-³¹p� | 1 |
1319 | q� | 19 |
1320 | maq� | 1 |
1321 | mbq� | 2 |
1322 | coenzymeq� | 1 |
1323 | sterolq� | 4 |
1324 | coq� | 27 |
1325 | r� | 12 |
1326 | glp1r� | 2 |
1327 | “unclear� | 1 |
1328 | year� | 4 |
1329 | “regular� | 1 |
1330 | star� | 4 |
1331 | al₆₆ti₂₄cr� | 2 |
1332 | al₅₉ti₂₆cr� | 2 |
1333 | dr� | 2 |
1334 | -dr� | 1 |
1335 | er� | 2 |
1336 | steer� | 1 |
1337 | rac·steer� | 4 |
1338 | mg·steer� | 1 |
1339 | “proper� | 1 |
1340 | ser� | 8 |
1341 | liter� | 4 |
1342 | experimenter� | 1 |
1343 | observer� | 1 |
1344 | hr� | 2 |
1345 | “fair� | 1 |
1346 | ldlr� | 4 |
1347 | slr� | 1 |
1348 | ventilator� | 1 |
1349 | qids-sr� | 2 |
1350 | ml·yr� | 1 |
1351 | s� | 35 |
1352 | l₅-s� | 1 |
1353 | cs� | 1 |
1354 | “aces� | 1 |
1355 | attitudes� | 1 |
1356 | outcomes� | 2 |
1357 | databases� | 2 |
1358 | audadis� | 1 |
1359 | seis� | 1 |
1360 | his� | 1 |
1361 | arthritis� | 1 |
1362 | “aminals� | 1 |
1363 | ms� | 1 |
1364 | beta-lactams� | 1 |
1365 | symptoms� | 2 |
1366 | “statins� | 1 |
1367 | lessons� | 1 |
1368 | chos� | 10 |
1369 | disorders� | 1 |
1370 | hours� | 1 |
1371 | mass� | 3 |
1372 | cross� | 1 |
1373 | patients� | 1 |
1374 | reviews� | 1 |
1375 | m·s� | 3 |
1376 | n·s� | 4 |
1377 | t� | 82 |
1378 | dgemric-t� | 5 |
1379 | t₅-t� | 1 |
1380 | /t� | 1 |
1381 | t₄/t� | 2 |
1382 | at� | 22 |
1383 | losartan-at� | 1 |
1384 | arbs-at� | 1 |
1385 | beat� | 1 |
1386 | esat� | 4 |
1387 | hbt� | 3 |
1388 | diet� | 2 |
1389 | comet� | 1 |
1390 | igt� | 7 |
1391 | 5-ht� | 6 |
1392 | weight� | 1 |
1393 | h₂cit� | 1 |
1394 | hit� | 3 |
1395 | carakasamhit� | 1 |
1396 | �/c-kit� | 1 |
1397 | lt� | 4 |
1398 | blt� | 1 |
1399 | mt� | 2 |
1400 | “unpleasant� | 1 |
1401 | “pleasant� | 1 |
1402 | assessment� | 1 |
1403 | event� | 1 |
1404 | pt� | 4 |
1405 | “sport� | 1 |
1406 | post� | 11 |
1407 | mirtazapine–first� | 1 |
1408 | sst� | 1 |
1409 | wt� | 3 |
1410 | ads₃×s³×t� | 1 |
1411 | rorγt� | 5 |
1412 | �t� | 1 |
1413 | u� | 3 |
1414 | �/u� | 2 |
1415 | hu� | 1 |
1416 | chu� | 1 |
1417 | shu� | 1 |
1418 | ku� | 1 |
1419 | glu� | 1 |
1420 | mu� | 1 |
1421 | v� | 8 |
1422 | cv� | 5 |
1423 | fev� | 172 |
1424 | δpre-fev� | 4 |
1425 | δpost-fev� | 4 |
1426 | wmfev� | 3 |
1427 | δfev� | 3 |
1428 | hiv� | 16 |
1429 | µv� | 2 |
1430 | w� | 7 |
1431 | aw� | 1 |
1432 | qaw� | 1 |
1433 | bw� | 2 |
1434 | interview� | 1 |
1435 | low� | 5 |
1436 | follow� | 1 |
1437 | α-pw� | 4 |
1438 | acyw� | 1 |
1439 | x� | 2 |
1440 | mp2x� | 2 |
1441 | max� | 3 |
1442 | suvmax� | 1 |
1443 | dx� | 1 |
1444 | ex� | 1 |
1445 | sex� | 4 |
1446 | y� | 1 |
1447 | p2y� | 13 |
1448 | day� | 41 |
1449 | �¹.day� | 1 |
1450 | �¹∙day� | 4 |
1451 | �¹·day� | 4 |
1452 | intimacy� | 1 |
1453 | “efficiency� | 1 |
1454 | morphology� | 1 |
1455 | dhy� | 1 |
1456 | sankhy� | 2 |
1457 | hiy� | 1 |
1458 | malaky� | 1 |
1459 | family� | 1 |
1460 | “early� | 1 |
1461 | regularly� | 1 |
1462 | ry� | 1 |
1463 | laboratory� | 1 |
1464 | kulliyy� | 1 |
1465 | z� | 3 |
1466 | zhèngz� | 1 |
1467 | arz� | 2 |
1468 | |� | 2 |
1469 | � | 1 |
1470 | π� | 1 |
1471 | с� | 1 |
1472 | ₂� | 4 |
1473 | apob/lp-pla₂� | 4 |
1474 | c₂� | 5 |
1475 | d₂� | 2 |
1476 | ce₃o₅d₂� | 1 |
1477 | ntf₂� | 1 |
1478 | k₂� | 1 |
1479 | n₂� | 1 |
1480 | o₂� | 7 |
1481 | no₂� | 15 |
1482 | t₂₂� | 1 |
1483 | ₃� | 2 |
1484 | c₃� | 1 |
1485 | d₃� | 3 |
1486 | hco₃� | 18 |
1487 | no₃� | 11 |
1488 | ²h-³¹p₃� | 1 |
1489 | au₃� | 2 |
1490 | ₋₃� | 9 |
1491 | aβ₃� | 5 |
1492 | σ� | 6 |
1493 | ₄� | 1 |
1494 | bf₄� | 1 |
1495 | nh₄� | 2 |
1496 | nh₃/nh₄� | 2 |
1497 | clo₄� | 2 |
1498 | baclo₄� | 1 |
1499 | ce₂o₄� | 2 |
1500 | 大黃附� | 1 |
1501 | δa₅� | 2 |
1502 | κoλλυ� | 1 |
1503 | pf₆� | 1 |
1504 | ce₃o₆� | 2 |
1505 | pc₇� | 2 |
1506 | α₄β₇� | 2 |
1507 | ∇� | 1 |
1508 | 妇� | 1 |
1509 | t₈� | 2 |
1510 | ₉� | 1 |
1511 | ω� | 1 |
1512 | ₋� | 5 |
1513 | mmhg₋� | 6 |
1514 | kg₋� | 2 |
1515 | log₋� | 2 |
1516 | min₋� | 7 |
1517 | 2.8±0.3mlmin₋� | 1 |
1518 | 3.9±0.5mlmin₋� | 1 |
1519 | ₀₋� | 1 |
1520 | auc₀₋� | 10 |
1521 | -auc₀₋� | 2 |
1522 | 0→� | 2 |
1523 | ⇒� | 1 |
1524 | 血府� | 1 |
1525 | abts•� | 1 |
1526 | o₂•� | 1 |
1527 | α� | 17 |
1528 | cpα� | 1 |
1529 | ²� | 22 |
1530 | ba²� | 2 |
1531 | ca²� | 150 |
1532 | ip₃-ca²� | 1 |
1533 | �/ca²� | 1 |
1534 | cd²� | 2 |
1535 | be²� | 5 |
1536 | fe²� | 12 |
1537 | �/fe²� | 1 |
1538 | hg²� | 10 |
1539 | mg²� | 32 |
1540 | �+mg²� | 2 |
1541 | high-mg²� | 2 |
1542 | �-mg²� | 2 |
1543 | ni²� | 4 |
1544 | mn²� | 6 |
1545 | zn²� | 12 |
1546 | co²� | 7 |
1547 | asp²� | 1 |
1548 | lys²� | 4 |
1549 | �/hcit²� | 1 |
1550 | cu²� | 17 |
1551 | ₃²� | 1 |
1552 | co₃²� | 1 |
1553 | mncl₄²� | 1 |
1554 | mnbr₄²� | 1 |
1555 | mnx₄²� | 1 |
1556 | �/mnx₄²� | 1 |
1557 | cr₂o₇²� | 1 |
1558 | χ²� | 5 |
1559 | ¹²� | 13 |
1560 | met¹²� | 1 |
1561 | �²� | 1 |
1562 | β� | 26 |
1563 | tgf-β� | 8 |
1564 | factor-β� | 1 |
1565 | aβ� | 3 |
1566 | tgfβ� | 3 |
1567 | △� | 2 |
1568 | 平� | 1 |
1569 | ³� | 10 |
1570 | ala³� | 1 |
1571 | �-ala³� | 2 |
1572 | tb³� | 1 |
1573 | �-tb³� | 1 |
1574 | yb³� | 28 |
1575 | �-yb³� | 3 |
1576 | �/yb³� | 2 |
1577 | �₋yb³� | 1 |
1578 | gd³� | 2 |
1579 | nd³� | 13 |
1580 | ce³� | 8 |
1581 | fe³� | 12 |
1582 | re³� | 2 |
1583 | arg³� | 2 |
1584 | al³� | 11 |
1585 | tm³� | 5 |
1586 | �/tm³� | 1 |
1587 | ln³� | 4 |
1588 | co³� | 1 |
1589 | ho³� | 10 |
1590 | �/ho³� | 1 |
1591 | cr³� | 5 |
1592 | er³� | 15 |
1593 | �/er³� | 4 |
1594 | �-ser³� | 1 |
1595 | thr³� | 2 |
1596 | pr³� | 2 |
1597 | lys³� | 1 |
1598 | au³� | 8 |
1599 | eu³� | 9 |
1600 | y³� | 1 |
1601 | dy³� | 2 |
1602 | gly³� | 1 |
1603 | �-gly³� | 1 |
1604 | ₃³� | 2 |
1605 | ²³� | 6 |
1606 | �/� | 2 |
1607 | hspg2� | 2 |
1608 | ¹³� | 38 |
1609 | γ� | 2 |
1610 | δ� | 28 |
1611 | rδ� | 5 |
1612 | �¹·min·� | 3 |
1613 | ·pro·� | 1 |
1614 | o₂·� | 5 |
1615 | η� | 2 |
1616 | ¹� | 83 |
1617 | 1-¹� | 1 |
1618 | methyl-¹� | 1 |
1619 | u-¹� | 1 |
1620 | glycolyl-u-¹� | 2 |
1621 | phenyl-u-¹� | 2 |
1622 | 10¹� | 4 |
1623 | 1.2×10¹� | 1 |
1624 | 5.6×10¹� | 1 |
1625 | 3.9×10¹� | 1 |
1626 | ≥10¹� | 2 |
1627 | c¹� | 1 |
1628 | �³eseekawqklcsl¹� | 1 |
1629 | met¹� | 1 |
1630 | glu¹� | 1 |
1631 | δ¹� | 12 |
1632 | ser¹¹� | 1 |
1633 | �¹� | 6 |
1634 | κ� | 1 |
1635 | рм� | 1 |
1636 | �� | 178 |
1637 | ν� | 3 |